Save up to 80% by drug discount in your pharmacy with "Pharmacy Near Me - National Drug Discount Card"
You can scan QR Code(just open camera on your phone/scan by application) from the image on prescription drug discount card to save it to your mobile phone. Or just click on image if you're on mobile phone.
| Product NDC Code | 72205-003 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| Drug Name | Rosuvastatin calcium |
||||||||||
| Type | Generic | ||||||||||
| Pharm Class | HMG-CoA Reductase Inhibitor [EPC], Hydroxymethylglutaryl-CoA Reductase Inhibitors [MoA] |
||||||||||
| Active Ingredients |
|
||||||||||
| Route | ORAL | ||||||||||
| Dosage Form | TABLET, FILM COATED | ||||||||||
| RxCUI drug identifier | 859419, 859424, 859747, 859751 |
||||||||||
| Application Number | ANDA208898 | ||||||||||
| Labeler Name | Novadoz Pharmaceuticals LLC | ||||||||||
| Packages |
|
||||||||||
| Check if available Online | Get Medication Prices online with Discount |
Overdosage of Rosuvastatin Calcium
Information about signs, symptoms, and laboratory findings of acute ovedosage and the general principles of overdose treatment.10 OVERDOSAGE No specific antidotes for rosuvastatin calcium are known. Hemodialysis does not significantly enhance clearance of rosuvastatin. Contact Poison Control (1-800-222-1222) for latest recommendations.
Adverse reactions
Information about undesirable effects, reasonably associated with use of the drug, that may occur as part of the pharmacological action of the drug or may be unpredictable in its occurrence. Adverse reactions include those that occur with the drug, and if applicable, with drugs in the same pharmacologically active and chemically related class. There is considerable variation in the listing of adverse reactions. They may be categorized by organ system, by severity of reaction, by frequency, by toxicological mechanism, or by a combination of these.6 ADVERSE REACTIONS The following important adverse reactions are described below and elsewhere in the labeling: Myopathy and Rhabdomyolysis [ see Warnings and Precautions (5.1) ] Immune-Mediated Necrotizing Myopathy [ see Warnings and Precautions (5.2) ] Hepatic Dysfunction [ see Warnings and Precautions (5.3) ] Proteinuria and Hematuria [ see Warnings and Precautions (5.4) ] Increases in HbA1c and Fasting Serum Glucose Levels [ see Warnings and Precautions (5.5) ] Most frequent adverse reactions (rate ≥2%) are headache, nausea, myalgia, asthenia, and constipation. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Novadoz Pharmaceuticals LLC at 1-855-668-2369 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch . 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. Adverse reactions reported in ≥2% of patients in placebo-controlled clinical studies and at a rate greater than placebo are shown in Table 2. These studies had a treatment duration of up to 12 weeks. Table 2: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin calcium and > Placebo in Placebo-Controlled Trials Adverse Reactions Placebo N=382 % Rosuvastatin calcium 5 mg N=291 % Rosuvastatin calcium 10 mg N=283 % Rosuvastatin calcium 20 mg N=64 % Rosuvastatin calcium 40 mg N=106 % Total Rosuvastatin calcium 5 mg-40 mg N=744 % Headache 5.0 5.5 4.9 3.1 8.5 5.5 Nausea 3.1 3.8 3.5 6.3 0 3.4 Myalgia 1.3 3.1 2.1 6.3 1.9 2.8 Asthenia 2.6 2.4 3.2 4.7 0.9 2.7 Constipation 2.4 2.1 2.1 4.7 2.8 2.4 Other adverse reactions reported in clinical studies were abdominal pain, dizziness, hypersensitivity (including rash, pruritus, urticaria, and angioedema) and pancreatitis. The following laboratory abnormalities have also been reported: dipstick-positive proteinuria and microscopic hematuria; elevated creatine phosphokinase, transaminases, glucose, glutamyl transpeptidase, alkaline phosphatase, and bilirubin; and thyroid function abnormalities. In the METEOR study, patients were treated with rosuvastatin calcium 40 mg (n=700) or placebo (n=281) with a mean treatment duration of 1.7 years. Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 3. Table 3: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin calcium and > Placebo in the METEOR Trial Adverse Reactions Placebo N=281 % Rosuvastatin calcium 40 mg N=700 % Myalgia 12.1 12.7 Arthralgia 7.1 10.1 Headache 5.3 6.4 Dizziness 2.8 4.0 Increased CPK 0.7 2.6 Abdominal pain 1.8 2.4 ALT greater than 3x ULN 1 0.7 2.2 1 Frequency recorded as abnormal laboratory value. In the JUPITER study, patients were treated with rosuvastatin calcium 20 mg (n=8901) or placebo (n=8901) for a mean duration of 2 years. In JUPITER, there was a significantly higher frequency of diabetes mellitus reported in patients taking rosuvastatin calcium (2.8%) versus patients taking placebo (2.3%). Mean HbA1c was significantly increased by 0.1% in rosuvastatin calcium-treated patients compared to placebo-treated patients. The number of patients with a HbA1c >6.5% at the end of the trial was significantly higher in rosuvastatin calcium-treated versus placebo-treated patients [see Clinical Studies (14) ]. Adverse reactions reported in ≥2% of patients and at a rate greater than placebo are shown in Table 4. Table 4: Adverse Reactions Reported in ≥2% of Patients Treated with Rosuvastatin calcium and > Placebo in the JUPITER Trial Adverse Reactions Placebo N=8901 % Rosuvastatin calcium 20 mg N=8901 % Myalgia 6.6 7.6 Arthralgia 3.2 3.8 Constipation 3.0 3.3 Diabetes mellitus 2.3 2.8 Nausea 2.3 2.4 Pediatric Patients with HeFH In a 12-week controlled study in pediatric patients 10 to 17 years of age with HeFH with rosuvastatin calcium 5 to 20 mg daily [ see Use in Specific Populations (8.4) and Clinical Studies (14) ] , elevations in serum CK greater than 10 x ULN were observed more frequently in rosuvastatin calcium-treated patients compared with patients receiving placebo. Four of 130 (3%) patients treated with rosuvastatin calcium (2 treated with 10 mg and 2 treated with 20 mg) had increased CK greater than 10 x ULN, compared to 0 of 46 patients on placebo. 6.2 Postmarketing Experience The following adverse reactions have been identified during postapproval use of rosuvastatin calcium. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. Blood Disorders: thrombocytopenia Hepatobiliary Disorders: hepatitis, jaundice, fatal and non-fatal hepatic failure Musculoskeletal Disorders: arthralgia, rare reports of immune-mediated necrotizing myopathy associated with statin use Nervous System Disorders: peripheral neuropathy, rare postmarketing reports of cognitive impairment (e.g., memory loss, forgetfulness, amnesia, memory impairment, and confusion) associated with the use of all statins. The reports are generally nonserious, and reversible upon statin discontinuation, with variable times to symptom onset (1 day to years) and symptom resolution (median of 3 weeks). There have been rare reports of new-onset or exacerbation of myasthenia gravis, including ocular myasthenia, and reports of recurrence when the same or a different statin was administered. Psychiatric Disorders: depression, sleep disorders (including insomnia and nightmares) Reproductive System and Breast Disorders: gynecomastia Respiratory Disorders: interstitial lung disease Skin and Subcutaneous Tissue Disorders: drug reaction with eosinophilia and systemic symptoms (DRESS), lichenoid drug eruption
| | | | | | | |
| Headache | 5.0 | 5.5 | 4.9 | 3.1 | 8.5 | 5.5 |
| Nausea | 3.1 | 3.8 | 3.5 | 6.3 | 0 | 3.4 |
| Myalgia | 1.3 | 3.1 | 2.1 | 6.3 | 1.9 | 2.8 |
| Asthenia | 2.6 | 2.4 | 3.2 | 4.7 | 0.9 | 2.7 |
| Constipation | 2.4 | 2.1 | 2.1 | 4.7 | 2.8 | 2.4 |
| | | |
| Myalgia | 12.1 | 12.7 |
| Arthralgia | 7.1 | 10.1 |
| Headache | 5.3 | 6.4 |
| Dizziness | 2.8 | 4.0 |
| Increased CPK | 0.7 | 2.6 |
| Abdominal pain | 1.8 | 2.4 |
| ALT greater than 3x ULN | 0.7 | 2.2 |
| | | |
| Myalgia | 6.6 | 7.6 |
| Arthralgia | 3.2 | 3.8 |
| Constipation | 3.0 | 3.3 |
| Diabetes mellitus | 2.3 | 2.8 |
| Nausea | 2.3 | 2.4 |
Rosuvastatin Calcium Drug Interactions
Information about and practical guidance on preventing clinically significant drug/drug and drug/food interactions that may occur in people taking the drug.7 DRUG INTERACTIONS See full prescribing information for details regarding concomitant use of rosuvastatin calcium with other drugs that increase the risk of myopathy and rhabdomyolysis. ( 2.6 , 7.1 ) Aluminum and Magnesium Hydroxide Combination Antacids: Administer rosuvastatin calcium at least 2 hours after the antacid. ( 2.6 , 7.2 ) Wafarin: Obtain INR prior to starting rosuvastatin calcium. Monitor INR frequently until stable upon initiation, dose titration or discontinuation. ( 7.3 ) 7.1 Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin calcium Rosuvastatin is a substrate of CYP2C9 and transporters (such as OATP1B1, BCRP). Rosuvastatin plasma levels can be significantly increased with concomitant administration of inhibitors of CYP2C9 and transporters. Table 5 includes a list of drugs that increase the risk of myopathy and rhabdomyolysis when used concomitantly with rosuvastatin calcium and instructions for preventing or managing them [see Warnings and Precautions (5.1) and Clinical Pharmacology (12.3)]. Table 5: Drug Interactions that Increase the Risk of Myopathy and Rhabdomyolysis with Rosuvastatin calcium Cyclosporine Clinical Impact: Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with rosuvastatin calcium. Intervention: If used concomitantly, do not exceed a dose of rosuvastatin calcium 5 mg once daily . Teriflunomide Clinical Impact: Teriflunomide increased rosuvastatin exposure more than 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Intervention: In patients taking teriflunomide, do not exceed a dose of rosuvastatin calcium 10 mg once daily . Enasidenib Clinical Impact: Enasidenib increased rosuvastatin exposure more than 2.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Intervention: In patients taking enasidenib, do not exceed a dose of rosuvastatin 10 mg once daily . Capmatinib Clinical Impact: Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Intervention: In patients taking capmatinib, do not exceed a dose of rosuvastatin calcium 10 mg once daily . Fostamatinib Clinical Impact: Fostamatinib increased rosuvastatin exposure more than 2.0-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Intervention: In patients taking fostamatinib, do not exceed a dose of rosuvastatin calcium 20 mg once daily . Febuxostat Clinical Impact: Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. Intervention: In patients taking febuxostat, do not exceed a dose of rosuvastatin calcium 20 mg once daily . Gemfibrozil Clinical Impact: Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with rosuvastatin calcium. Intervention: Avoid concomitant use of gemfibrozil with rosuvastatin calcium. If used concomitantly, initiate rosuvastatin calcium at 5 mg once daily and do not exceed a dose of rosuvastatin calcium 10 mg once daily . Tafamidis Clinical Impact: Tafamidis significantly increased rosuvastatin exposure and tafamidis may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of tafamidis with rosuvastatin calcium. Intervention: Avoid concomitant use of tafamidis with rosuvastatin calcium. If used concomitantly, initiate rosuvastatin calcium at 5 mg once daily and do not exceed a dose of rosuvastatin calcium 20 mg once daily. Monitor for signs of myopathy and rhabdomyolysis if used concomitantly with rosuvastatin calcium . Anti-Viral Medications Clinical Impact: Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis. Intervention: Sofosbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Avoid concomitant use with rosuvastatin calcium. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/grazoprevir Sofosbuvir/velpatasvir Glecaprevir/pibrentasvir Atazanavir/ritonavir Lopinavir/ritonavir Initiate with rosuvastatin calcium 5 mg once daily, and do not exceed a dose of rosuvastatin calcium 10 mg once daily. Darolutamide Clinical Impact: Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use . Intervention: In patients taking darolutamide, do not exceed a dose of rosuvastatin calcium 5 mg once daily . Regorafenib Clinical Impact: Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. Intervention: In patients taking regorafenib, do not exceed a dose of rosuvastatin calcium 10 mg once daily . Fenofibrates (e.g., fenofibrate and fenofibric acid) Clinical Impact: Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with rosuvastatin calcium. Intervention: Consider if the benefit of using fibrates concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. Niacin Clinical Impact: Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying doses (≥1 g/day) of niacin with rosuvastatin calcium. Intervention: Consider if the benefit of using lipid-modifying doses (≥1 g/day) of niacin concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. Colchicine Clinical Impact: Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with rosuvastatin calcium. Intervention: Consider if the benefit of using colchicine concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. 7.2 Drug Interactions that Decrease the Efficacy of Rosuvastatin calcium Table 6 presents drug interactions that may decrease the efficacy of rosuvastatin calcium and instructions for preventing or managing them. Table 6: Drug Interactions that Decrease the Efficacy of Rosuvastatin calcium Antacids Clinical Impact: Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% [see Clinical Pharmacology (12.3)]. Intervention: In patients taking antacid, administer rosuvastatin calcium at least 2 hours after the antacid . 7.3 Rosuvastatin calcium Effects on Other Drugs Table 7 presents rosuvastatin calcium effect on other drugs and instructions for preventing or managing them. Table 7: Rosuvastatin calcium Effects on Other Drugs Warfarin Clinical Impact: Rosuvastatin significantly increased the INR in patients receiving warfarin [see Clinical Pharmacology (12.3)]. Intervention: In patients taking warfarin, obtain an INR before starting rosuvastatin calcium and frequently enough after initiation, dose titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals.
| | ||
| | Cyclosporine increased rosuvastatin exposure 7-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use of cyclosporine or gemfibrozil with rosuvastatin calcium. | |
| | If used concomitantly, do not exceed a dose of rosuvastatin calcium 5 mg once daily | |
| | ||
| | Teriflunomide increased rosuvastatin exposure more than 2.5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. | |
| | In patients taking teriflunomide, do not exceed a dose of rosuvastatin calcium 10 mg once daily | |
| | ||
| | Enasidenib increased rosuvastatin exposure more than 2.4-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. | |
| | In patients taking enasidenib, do not exceed a dose of rosuvastatin 10 mg once daily | |
| | ||
| | Capmatinib increased rosuvastatin exposure more than 2.1-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. | |
| | In patients taking capmatinib, do not exceed a dose of rosuvastatin calcium 10 mg once daily | |
| | ||
| | Fostamatinib increased rosuvastatin exposure more than 2.0-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. | |
| | In patients taking fostamatinib, do not exceed a dose of rosuvastatin calcium 20 mg once daily | |
| | ||
| | Febuxostat increased rosuvastatin exposure more than 1.9-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use. | |
| | In patients taking febuxostat, do not exceed a dose of rosuvastatin calcium 20 mg once daily | |
| | ||
| | Gemfibrozil significantly increased rosuvastatin exposure and gemfibrozil may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of gemfibrozil with rosuvastatin calcium. | |
| | Avoid concomitant use of gemfibrozil with rosuvastatin calcium. If used concomitantly, initiate rosuvastatin calcium at 5 mg once daily and do not exceed a dose of rosuvastatin calcium 10 mg once daily | |
| | ||
| | Tafamidis significantly increased rosuvastatin exposure and tafamidis may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of tafamidis with rosuvastatin calcium. | |
| | Avoid concomitant use of tafamidis with rosuvastatin calcium. If used concomitantly, initiate rosuvastatin calcium at 5 mg once daily and do not exceed a dose of rosuvastatin calcium 20 mg once daily. Monitor for signs of myopathy and rhabdomyolysis if used concomitantly with rosuvastatin calcium | |
| | ||
| | Rosuvastatin plasma levels were significantly increased with concomitant administration of many anti-viral drugs, which increases the risk of myopathy and rhabdomyolysis. | |
| |
| Avoid concomitant use with rosuvastatin calcium. |
| Initiate with rosuvastatin calcium 5 mg once daily, and do not exceed a dose of rosuvastatin calcium 10 mg once daily. | |
| | ||
| | Darolutamide increased rosuvastatin exposure more than 5-fold. The risk of myopathy and rhabdomyolysis is increased with concomitant use | |
| | In patients taking darolutamide, do not exceed a dose of rosuvastatin calcium 5 mg once daily | |
| | ||
| | Regorafenib increased rosuvastatin exposure and may increase the risk of myopathy. | |
| | In patients taking regorafenib, do not exceed a dose of rosuvastatin calcium 10 mg once daily | |
| | ||
| | Fibrates may cause myopathy when given alone. The risk of myopathy and rhabdomyolysis is increased with concomitant use of fibrates with rosuvastatin calcium. | |
| | Consider if the benefit of using fibrates concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. | |
| | ||
| | Cases of myopathy and rhabdomyolysis have occurred with concomitant use of lipid-modifying doses (≥1 g/day) of niacin with rosuvastatin calcium. | |
| | Consider if the benefit of using lipid-modifying doses (≥1 g/day) of niacin concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. | |
| | ||
| | Cases of myopathy and rhabdomyolysis have been reported with concomitant use of colchicine with rosuvastatin calcium. | |
| | Consider if the benefit of using colchicine concomitantly with rosuvastatin calcium outweighs the increased risk of myopathy and rhabdomyolysis. If concomitant use is decided, monitor patients for signs and symptoms of myopathy, particularly during initiation of therapy and during upward dose titration of either drug. | |
| | |
| | Concomitant aluminum and magnesium hydroxide combination antacid administration decreased the mean exposure of rosuvastatin 50% |
| | In patients taking antacid, administer rosuvastatin calcium at least 2 hours after the antacid . |
| | |
| | Rosuvastatin significantly increased the INR in patients receiving warfarin |
| | In patients taking warfarin, obtain an INR before starting rosuvastatin calcium and frequently enough after initiation, dose titration or discontinuation to ensure that no significant alteration in INR occurs. Once the INR is stable, monitor INR at regularly recommended intervals. |
Clinical pharmacology
Information about the clinical pharmacology and actions of the drug in humans.12 CLINICAL PHARMACOLOGY 12.1 Mechanism of Action Rosuvastatin calcium is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol. 12.2 Pharmacodynamics Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of rosuvastatin calcium is usually achieved by 4 weeks and is maintained after that. 12.3 Pharmacokinetics Absorption In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C max and AUC increased in approximate proportion to rosuvastatin calcium dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration. Effect of food Administration of rosuvastatin calcium with food did not affect the AUC of rosuvastatin. Distribution Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations. Elimination Metabolism Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound. Excretion Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours. Specific Populations Geriatric Patients There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years). Pediatric Patients In a population pharmacokinetic analysis of two pediatric trials involving patients with heterozygous familial hypercholesterolemia 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients. Male and Female Patients There were no differences in plasma concentrations of rosuvastatin between men and women. Racial or Ethnic Groups A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and C max ) in Asian subjects when compared with a Caucasian control group. Patients with Renal Impairment Mild to moderate renal impairment (CL cr ≥30 mL/min/1.73 m 2 ) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3-fold) in patients with severe renal impairment (CL cr <30 mL/min/1.73 m 2 ) not receiving hemodialysis compared with healthy subjects (CL cr >80 mL/min/1.73 m 2 ). Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function. Patients with Hepatic Impairment In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased. In patients with Child-Pugh A disease, C max and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, C max and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function. Drug Interactions Studies Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin calcium with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations [ see Dosage and Administration (2.6) and Drug Interactions (7.1) ]. Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure Coadministered drug and dosing regimen Rosuvastatin Mean Ratio (ratio with/without coadministered drug) No Effect=1.0 Dose (mg) 1 Change in AUC Change in C max Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days 10 mg, single dose 7.39 2 (6.68-8.18) 3 18.88 2 (16.23-21.96) 3 Cyclosporine – stable dose required (75 mg – 200 mg BID) 10 mg, QD for 10 days 7.1 2 11 2 Darolutamide 600 mg BID, 5 days 5 mg, single dose 5.2 2 ~5 2 Regorafenib 160 mg QD, 14 days 5 mg, single dose 3.8 2 4.6 2 Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days 10 mg 3.1 2 7 2 Simeprevir 150 mg QD, 7 days 10 mg, single dose 2.8 2 (2.3-3.4) 3 3.2 2 (2.6-3.9) 3 Velpatasvir 100 mg once daily 10 mg, single dose 2.69 2 (2.46-2.94) 3 2.61 2 (2.32-2.92) 3 Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose 2.59 2 (2.09-3.21) 3 7.13 2 (5.11-9.96) 3 Teriflunomide Not available 2.51 2 2.65 2 Enasidenib 100 mg QD, 28 days 10 mg, single dose 2.44 3.66 Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose 2.26 2 (1.89-2.69) 3 5.49 2 (4.29-7.04) 3 Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg, once daily 2.15 2 (1.88-2.46) 3 5.62 2 (4.80-6.59) 3 Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg, QD for 7 days 2.1 2 (1.7-2.6) 3 5 2 (3.4-6.4) 3 Capmatinib 400 mg BID 10 mg, single dose 2.08 2 (1.56-2.76) 3 3.04 2 (2.36-3.92) 3 Fostamatinib 100 mg BID 20 mg, single dose 1.96 2 (1.77-2.15) 3 1.88 2 (1.69-2.09) 3 Febuxostat 120 mg OD for 4 days 10 mg, single dose 1.9 2 (1.5-2.5) 3 2.1 2 (1.8-2.6) 3 Gemfibrozil 600 mg BID for 7 days 80 mg 1.9 2 (1.6-2.2) 3 2.2 2 (1.8-2.7) 3 Tafamidis 61 mg QD, 7 days 10 mg 1.97 2 (1.68-2.31) 3 1.86 2 (1.59-2.16) 3 Eltrombopag 75 mg QD, 5 days 10 mg 1.6 (1.4-1.7) 3 2 (1.8-2.3) 3 Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg, QD for 7 days 1.5 (1.0-2.1) 3 2.4 (1.6-3.6) 3 Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days 10 mg 1.4 (1.2-1.6) 3 2.2 (1.8-2.7) 3 Dronedarone 400 mg BID 10 mg 1.4 Itraconazole 200 mg QD, 5 days 10 mg or 80 mg 1.4 (1.2-1.6) 3 1.3 (1.1-1.4) 3 1.4 (1.2-1.5) 3 1.2 (0.9-1.4) 3 Ezetimibe 10 mg QD, 14 days 10 mg, QD for 14 days 1.2 (0.9-1.6) 3 1.2 (0.8-1.6) 3 Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days 10 mg 1.1 1.5 Fenofibrate 67 mg TID for 7 days 10 mg ↔ 1.2 (1.1-1.3) 3 Rifampicin 450 mg QD, 7 days 20 mg ↔ Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart 40 mg 40 mg 0.5 2 (0.4-0.5) 3 0.8 (0.7-0.9) 3 0.5 2 (0.4-0.6) 3 0.8 (0.7-1.0) 3 Ketoconazole 200 mg BID for 7 days 80 mg 1.0 (0.8-1.2) 3 1.0 (0.7-1.3) 3 Fluconazole 200 mg QD for 11 days 80 mg 1.1 (1.0-1.3) 3 1.1 (0.9-1.4) 3 Erythromycin 500 mg QID for 7 days 80 mg 0.8 (0.7-0.9) 3 0.7 (0.5-0.9) 3 QD= Once daily, BID= Twice daily, TID= Three times daily, QID= Four times daily 1 Single dose unless otherwise noted. 2 Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)] 3 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11-fold increase in exposure) Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs Rosuvastatin Dosage Regimen Coadministered Drug Mean Ratio (ratio with/without coadministered drug) No Effect=1.0 Name and Dose Change in AUC Change in C max 40 mg QD for 10 days Warfarin 1 25 mg single dose R-Warfarin 1.0 (1.0-1.1) 2 S-Warfarin 1.1 (1.0-1.1) 2 R-Warfarin 1.0 (0.9-1.0) 2 S-Warfarin 1.0 (0.9-1.1) 2 40 mg QD for 12 days Digoxin 0.5 mg single dose 1.0 (0.9-1.2) 2 1.0 (0.9-1.2) 2 40 mg QD for 28 days Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days EE 1.3 (1.2-1.3) 2 NG 1.3 (1.3-1.4) 2 EE 1.3 (1.2-1.3) 2 NG 1.2 (1.1-1.3) 2 EE = ethinyl estradiol, NG = norgestrel, QD= Once daily 1 Clinically significant pharmacodynamic effects [see Drug Interactions (7.3)] 2 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure) 12.5 Pharmacogenomics Disposition of rosuvastatin, involves OATP1B1 and other transporter proteins. Higher plasma concentrations of rosuvastatin have been reported in very small groups of patients (n=3 to 5) who have two reduced function alleles of the gene that encodes OATP1B1 ( SLCO1B1 521T > C). The frequency of this genotype (i.e., SLCO1B1 521 C/C) is generally lower than 5% in most racial/ethnic groups. The impact of this polymorphism on efficacy and/or safety of rosuvastatin calcium has not been clearly established.
| | | ||
| | |||
| | | | |
| Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days | 10 mg, single dose | 7.39 | 18.88 |
| Cyclosporine – stable dose required (75 mg – 200 mg BID) | 10 mg, QD for 10 days | 7.1 | 11 |
| Darolutamide 600 mg BID, 5 days | 5 mg, single dose | 5.2 | ~5 |
| Regorafenib 160 mg QD, 14 days | 5 mg, single dose | 3.8 | 4.6 |
| Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days | 10 mg | 3.1 | 7 |
| Simeprevir 150 mg QD, 7 days | 10 mg, single dose | 2.8 | 3.2 |
| Velpatasvir 100 mg once daily | 10 mg, single dose | 2.69 | 2.61 |
| Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID | 5 mg, single dose | 2.59 | 7.13 |
| Teriflunomide | Not available | 2.51 | 2.65 |
| Enasidenib 100 mg QD, 28 days | 10 mg, single dose | 2.44 | 3.66 |
| Elbasvir 50 mg/grazoprevir 200 mg once daily | 10 mg, single dose | 2.26 | 5.49 |
| Glecaprevir 400 mg/pibrentasvir 120 mg once daily | 5 mg, once daily | 2.15 | 5.62 |
| Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days | 20 mg, QD for 7 days | 2.12 (1.7-2.6)3 | 52 (3.4-6.4)3 |
| Capmatinib 400 mg BID | 10 mg, single dose | 2.08 | 3.04 |
| Fostamatinib 100 mg BID | 20 mg, single dose | 1.96 | 1.88 |
| Febuxostat 120 mg OD for 4 days | 10 mg, single dose | 1.9 | 2.1 |
| Gemfibrozil 600 mg BID for 7 days | 80 mg | 1.9 | 2.2 |
| Tafamidis 61 mg QD, 7 days | 10 mg | 1.972 (1.68-2.31) | 1.862 (1.59-2.16) |
| Eltrombopag 75 mg QD, 5 days | 10 mg | 1.6 (1.4-1.7) | 2 (1.8-2.3) |
| Darunavir 600 mg/ritonavir 100 mg BID, 7 days | 10 mg, QD for 7 days | 1.5 (1.0-2.1) | 2.4 (1.6-3.6) |
| Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days | 10 mg | 1.4 (1.2-1.6) | 2.2 (1.8-2.7) |
| Dronedarone 400 mg BID | 10 mg | 1.4 | |
| Itraconazole 200 mg QD, 5 days | 10 mg or 80 mg | 1.4 (1.2-1.6) | 1.4 (1.2-1.5) |
| Ezetimibe 10 mg QD, 14 days | 10 mg, QD for 14 days | 1.2 (0.9-1.6) | 1.2 (0.8-1.6) |
| Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days | 10 mg | 1.1 | 1.5 |
| Fenofibrate 67 mg TID for 7 days | 10 mg | ↔ | 1.2 (1.1-1.3) |
| Rifampicin 450 mg QD, 7 days | 20 mg | ↔ | |
| Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart | 40 mg 40 mg | 0.5 | 0.5 |
| Ketoconazole 200 mg BID for 7 days | 80 mg | 1.0 (0.8-1.2) | 1.0 (0.7-1.3) |
| Fluconazole 200 mg QD for 11 days | 80 mg | 1.1 (1.0-1.3) | 1.1 (0.9-1.4) |
| Erythromycin 500 mg QID for 7 days | 80 mg | 0.8 (0.7-0.9) | 0.7 (0.5-0.9) |
| | | ||
| | |||
| | | | |
| 40 mg QD for 10 days | Warfarin | R-Warfarin 1.0 (1.0-1.1) | R-Warfarin 1.0 (0.9-1.0) |
| 40 mg QD for 12 days | Digoxin 0.5 mg single dose | 1.0 (0.9-1.2) | 1.0 (0.9-1.2)2 |
| 40 mg QD for 28 days | Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days | EE 1.3 (1.2-1.3) | EE 1.3 (1.2-1.3) |
Mechanism of action
Information about the established mechanism(s) of the drugÕs action in humans at various levels (for example receptor, membrane, tissue, organ, whole body). If the mechanism of action is not known, this field contains a statement about the lack of information.12.1 Mechanism of Action Rosuvastatin calcium is an inhibitor of HMG-CoA reductase, the rate-limiting enzyme that converts 3-hydroxy-3-methylglutaryl coenzyme A to mevalonate, a precursor of cholesterol.
Pharmacodynamics
Information about any biochemical or physiologic pharmacologic effects of the drug or active metabolites related to the drugÕs clinical effect in preventing, diagnosing, mitigating, curing, or treating disease, or those related to adverse effects or toxicity.12.2 Pharmacodynamics Inhibition of HMG-CoA reductase by rosuvastatin accelerates the expression of LDL-receptors, followed by the uptake of LDL-C from blood to the liver, leading to a decrease in plasma LDL-C and total cholesterol. Sustained inhibition of cholesterol synthesis in the liver also decreases levels of very-low-density lipoproteins. The maximum LDL-C reduction of rosuvastatin calcium is usually achieved by 4 weeks and is maintained after that.
Pharmacokinetics
Information about the clinically significant pharmacokinetics of a drug or active metabolites, for instance pertinent absorption, distribution, metabolism, and excretion parameters.12.3 Pharmacokinetics Absorption In clinical pharmacology studies in man, peak plasma concentrations of rosuvastatin were reached 3 to 5 hours following oral dosing. Both C max and AUC increased in approximate proportion to rosuvastatin calcium dose. The absolute bioavailability of rosuvastatin is approximately 20%. The AUC of rosuvastatin does not differ following evening or morning drug administration. Effect of food Administration of rosuvastatin calcium with food did not affect the AUC of rosuvastatin. Distribution Mean volume of distribution at steady-state of rosuvastatin is approximately 134 liters. Rosuvastatin is 88% bound to plasma proteins, mostly albumin. This binding is reversible and independent of plasma concentrations. Elimination Metabolism Rosuvastatin is not extensively metabolized; approximately 10% of a radiolabeled dose is recovered as metabolite. The major metabolite is N-desmethyl rosuvastatin, which is formed principally by cytochrome P450 \ 2C9, and in vitro studies have demonstrated that N-desmethyl rosuvastatin has approximately one-sixth to one-half the HMG-CoA reductase inhibitory activity of the parent compound. Overall, greater than 90% of active plasma HMG-CoA reductase inhibitory activity is accounted for by the parent compound. Excretion Following oral administration, rosuvastatin and its metabolites are primarily excreted in the feces (90%). After an intravenous dose, approximately 28% of total body clearance was via the renal route, and 72% by the hepatic route. The elimination half-life of rosuvastatin is approximately 19 hours. Specific Populations Geriatric Patients There were no differences in plasma concentrations of rosuvastatin between the nonelderly and elderly populations (age ≥65 years). Pediatric Patients In a population pharmacokinetic analysis of two pediatric trials involving patients with heterozygous familial hypercholesterolemia 10 to 17 years of age and 8 to 17 years of age, respectively, rosuvastatin exposure appeared comparable to or lower than rosuvastatin exposure in adult patients. Male and Female Patients There were no differences in plasma concentrations of rosuvastatin between men and women. Racial or Ethnic Groups A population pharmacokinetic analysis revealed no clinically relevant differences in pharmacokinetics among Caucasian, Hispanic, and Black or Afro-Caribbean groups. However, pharmacokinetic studies, including one conducted in the US, have demonstrated an approximate 2-fold elevation in median exposure (AUC and C max ) in Asian subjects when compared with a Caucasian control group. Patients with Renal Impairment Mild to moderate renal impairment (CL cr ≥30 mL/min/1.73 m 2 ) had no influence on plasma concentrations of rosuvastatin. However, plasma concentrations of rosuvastatin increased to a clinically significant extent (about 3-fold) in patients with severe renal impairment (CL cr <30 mL/min/1.73 m 2 ) not receiving hemodialysis compared with healthy subjects (CL cr >80 mL/min/1.73 m 2 ). Steady-state plasma concentrations of rosuvastatin in patients on chronic hemodialysis were approximately 50% greater compared with healthy volunteer subjects with normal renal function. Patients with Hepatic Impairment In patients with chronic alcohol liver disease, plasma concentrations of rosuvastatin were modestly increased. In patients with Child-Pugh A disease, C max and AUC were increased by 60% and 5%, respectively, as compared with patients with normal liver function. In patients with Child-Pugh B disease, C max and AUC were increased 100% and 21%, respectively, compared with patients with normal liver function. Drug Interactions Studies Rosuvastatin clearance is not dependent on metabolism by cytochrome P450 3A4 to a clinically significant extent. Rosuvastatin is a substrate for certain transporter proteins including the hepatic uptake transporter organic anion-transporting polyprotein 1B1 (OATP1B1) and efflux transporter breast cancer resistance protein (BCRP). Concomitant administration of rosuvastatin calcium with medications that are inhibitors of these transporter proteins (e.g. cyclosporine, certain HIV protease inhibitors) may result in increased rosuvastatin plasma concentrations [ see Dosage and Administration (2.6) and Drug Interactions (7.1) ]. Table 8: Effect of Coadministered Drugs on Rosuvastatin Systemic Exposure Coadministered drug and dosing regimen Rosuvastatin Mean Ratio (ratio with/without coadministered drug) No Effect=1.0 Dose (mg) 1 Change in AUC Change in C max Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days 10 mg, single dose 7.39 2 (6.68-8.18) 3 18.88 2 (16.23-21.96) 3 Cyclosporine – stable dose required (75 mg – 200 mg BID) 10 mg, QD for 10 days 7.1 2 11 2 Darolutamide 600 mg BID, 5 days 5 mg, single dose 5.2 2 ~5 2 Regorafenib 160 mg QD, 14 days 5 mg, single dose 3.8 2 4.6 2 Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days 10 mg 3.1 2 7 2 Simeprevir 150 mg QD, 7 days 10 mg, single dose 2.8 2 (2.3-3.4) 3 3.2 2 (2.6-3.9) 3 Velpatasvir 100 mg once daily 10 mg, single dose 2.69 2 (2.46-2.94) 3 2.61 2 (2.32-2.92) 3 Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID 5 mg, single dose 2.59 2 (2.09-3.21) 3 7.13 2 (5.11-9.96) 3 Teriflunomide Not available 2.51 2 2.65 2 Enasidenib 100 mg QD, 28 days 10 mg, single dose 2.44 3.66 Elbasvir 50 mg/grazoprevir 200 mg once daily 10 mg, single dose 2.26 2 (1.89-2.69) 3 5.49 2 (4.29-7.04) 3 Glecaprevir 400 mg/pibrentasvir 120 mg once daily 5 mg, once daily 2.15 2 (1.88-2.46) 3 5.62 2 (4.80-6.59) 3 Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days 20 mg, QD for 7 days 2.1 2 (1.7-2.6) 3 5 2 (3.4-6.4) 3 Capmatinib 400 mg BID 10 mg, single dose 2.08 2 (1.56-2.76) 3 3.04 2 (2.36-3.92) 3 Fostamatinib 100 mg BID 20 mg, single dose 1.96 2 (1.77-2.15) 3 1.88 2 (1.69-2.09) 3 Febuxostat 120 mg OD for 4 days 10 mg, single dose 1.9 2 (1.5-2.5) 3 2.1 2 (1.8-2.6) 3 Gemfibrozil 600 mg BID for 7 days 80 mg 1.9 2 (1.6-2.2) 3 2.2 2 (1.8-2.7) 3 Tafamidis 61 mg QD, 7 days 10 mg 1.97 2 (1.68-2.31) 3 1.86 2 (1.59-2.16) 3 Eltrombopag 75 mg QD, 5 days 10 mg 1.6 (1.4-1.7) 3 2 (1.8-2.3) 3 Darunavir 600 mg/ritonavir 100 mg BID, 7 days 10 mg, QD for 7 days 1.5 (1.0-2.1) 3 2.4 (1.6-3.6) 3 Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days 10 mg 1.4 (1.2-1.6) 3 2.2 (1.8-2.7) 3 Dronedarone 400 mg BID 10 mg 1.4 Itraconazole 200 mg QD, 5 days 10 mg or 80 mg 1.4 (1.2-1.6) 3 1.3 (1.1-1.4) 3 1.4 (1.2-1.5) 3 1.2 (0.9-1.4) 3 Ezetimibe 10 mg QD, 14 days 10 mg, QD for 14 days 1.2 (0.9-1.6) 3 1.2 (0.8-1.6) 3 Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days 10 mg 1.1 1.5 Fenofibrate 67 mg TID for 7 days 10 mg ↔ 1.2 (1.1-1.3) 3 Rifampicin 450 mg QD, 7 days 20 mg ↔ Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart 40 mg 40 mg 0.5 2 (0.4-0.5) 3 0.8 (0.7-0.9) 3 0.5 2 (0.4-0.6) 3 0.8 (0.7-1.0) 3 Ketoconazole 200 mg BID for 7 days 80 mg 1.0 (0.8-1.2) 3 1.0 (0.7-1.3) 3 Fluconazole 200 mg QD for 11 days 80 mg 1.1 (1.0-1.3) 3 1.1 (0.9-1.4) 3 Erythromycin 500 mg QID for 7 days 80 mg 0.8 (0.7-0.9) 3 0.7 (0.5-0.9) 3 QD= Once daily, BID= Twice daily, TID= Three times daily, QID= Four times daily 1 Single dose unless otherwise noted. 2 Clinically significant [see Dosage and Administration (2) and Warnings and Precautions (5)] 3 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7 = 30% decrease, 11=11-fold increase in exposure) Table 9: Effect of Rosuvastatin Coadministration on Systemic Exposure to Other Drugs Rosuvastatin Dosage Regimen Coadministered Drug Mean Ratio (ratio with/without coadministered drug) No Effect=1.0 Name and Dose Change in AUC Change in C max 40 mg QD for 10 days Warfarin 1 25 mg single dose R-Warfarin 1.0 (1.0-1.1) 2 S-Warfarin 1.1 (1.0-1.1) 2 R-Warfarin 1.0 (0.9-1.0) 2 S-Warfarin 1.0 (0.9-1.1) 2 40 mg QD for 12 days Digoxin 0.5 mg single dose 1.0 (0.9-1.2) 2 1.0 (0.9-1.2) 2 40 mg QD for 28 days Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days EE 1.3 (1.2-1.3) 2 NG 1.3 (1.3-1.4) 2 EE 1.3 (1.2-1.3) 2 NG 1.2 (1.1-1.3) 2 EE = ethinyl estradiol, NG = norgestrel, QD= Once daily 1 Clinically significant pharmacodynamic effects [see Drug Interactions (7.3)] 2 Mean ratio with 90% CI (with/without coadministered drug, e.g., 1= no change, 0.7=30% decrease, 11=11-fold increase in exposure)
| | | ||
| | |||
| | | | |
| Sofosbuvir/velpatasvir/voxilaprevir (400 mg-100 mg-100 mg) + Voxilaprevir (100 mg) once daily for 15 days | 10 mg, single dose | 7.39 | 18.88 |
| Cyclosporine – stable dose required (75 mg – 200 mg BID) | 10 mg, QD for 10 days | 7.1 | 11 |
| Darolutamide 600 mg BID, 5 days | 5 mg, single dose | 5.2 | ~5 |
| Regorafenib 160 mg QD, 14 days | 5 mg, single dose | 3.8 | 4.6 |
| Atazanavir/ritonavir combination 300 mg/100 mg QD for 8 days | 10 mg | 3.1 | 7 |
| Simeprevir 150 mg QD, 7 days | 10 mg, single dose | 2.8 | 3.2 |
| Velpatasvir 100 mg once daily | 10 mg, single dose | 2.69 | 2.61 |
| Ombitasvir 25 mg/paritaprevir 150 mg/ ritonavir 100 mg + dasabuvir 400 mg BID | 5 mg, single dose | 2.59 | 7.13 |
| Teriflunomide | Not available | 2.51 | 2.65 |
| Enasidenib 100 mg QD, 28 days | 10 mg, single dose | 2.44 | 3.66 |
| Elbasvir 50 mg/grazoprevir 200 mg once daily | 10 mg, single dose | 2.26 | 5.49 |
| Glecaprevir 400 mg/pibrentasvir 120 mg once daily | 5 mg, once daily | 2.15 | 5.62 |
| Lopinavir/ritonavir combination 400 mg/100 mg BID for 17 days | 20 mg, QD for 7 days | 2.12 (1.7-2.6)3 | 52 (3.4-6.4)3 |
| Capmatinib 400 mg BID | 10 mg, single dose | 2.08 | 3.04 |
| Fostamatinib 100 mg BID | 20 mg, single dose | 1.96 | 1.88 |
| Febuxostat 120 mg OD for 4 days | 10 mg, single dose | 1.9 | 2.1 |
| Gemfibrozil 600 mg BID for 7 days | 80 mg | 1.9 | 2.2 |
| Tafamidis 61 mg QD, 7 days | 10 mg | 1.972 (1.68-2.31) | 1.862 (1.59-2.16) |
| Eltrombopag 75 mg QD, 5 days | 10 mg | 1.6 (1.4-1.7) | 2 (1.8-2.3) |
| Darunavir 600 mg/ritonavir 100 mg BID, 7 days | 10 mg, QD for 7 days | 1.5 (1.0-2.1) | 2.4 (1.6-3.6) |
| Tipranavir/ritonavir combination 500 mg/200 mg BID for 11 days | 10 mg | 1.4 (1.2-1.6) | 2.2 (1.8-2.7) |
| Dronedarone 400 mg BID | 10 mg | 1.4 | |
| Itraconazole 200 mg QD, 5 days | 10 mg or 80 mg | 1.4 (1.2-1.6) | 1.4 (1.2-1.5) |
| Ezetimibe 10 mg QD, 14 days | 10 mg, QD for 14 days | 1.2 (0.9-1.6) | 1.2 (0.8-1.6) |
| Fosamprenavir/ritonavir 700 mg/100 mg BID for 7 days | 10 mg | 1.1 | 1.5 |
| Fenofibrate 67 mg TID for 7 days | 10 mg | ↔ | 1.2 (1.1-1.3) |
| Rifampicin 450 mg QD, 7 days | 20 mg | ↔ | |
| Aluminum & magnesium hydroxide combination antacid Administered simultaneously Administered 2 hours apart | 40 mg 40 mg | 0.5 | 0.5 |
| Ketoconazole 200 mg BID for 7 days | 80 mg | 1.0 (0.8-1.2) | 1.0 (0.7-1.3) |
| Fluconazole 200 mg QD for 11 days | 80 mg | 1.1 (1.0-1.3) | 1.1 (0.9-1.4) |
| Erythromycin 500 mg QID for 7 days | 80 mg | 0.8 (0.7-0.9) | 0.7 (0.5-0.9) |
| | | ||
| | |||
| | | | |
| 40 mg QD for 10 days | Warfarin | R-Warfarin 1.0 (1.0-1.1) | R-Warfarin 1.0 (0.9-1.0) |
| 40 mg QD for 12 days | Digoxin 0.5 mg single dose | 1.0 (0.9-1.2) | 1.0 (0.9-1.2)2 |
| 40 mg QD for 28 days | Oral Contraceptive (ethinyl estradiol 0.035 mg & norgestrel 0.180, 0.215 and 0.250 mg) QD for 21 Days | EE 1.3 (1.2-1.3) | EE 1.3 (1.2-1.3) |
Contraindications
Information about situations in which the drug product is contraindicated or should not be used because the risk of use clearly outweighs any possible benefit, including the type and nature of reactions that have been reported.4 CONTRAINDICATIONS Rosuvastatin calcium is contraindicated in the following conditions: Acute liver failure or decompensated cirrhosis [ see Warnings and Precautions (5.3) ]. Hypersensitivity to rosuvastatin or any excipients in rosuvastatin calcium. Hypersensitivity reactions including rash, pruritus, urticaria, and angioedema have been reported with rosuvastatin calcium [ see Adverse Reactions (6.1) ]. Acute liver failure or decompensated cirrhosis. ( 4 ) Hypersensitivity to rosuvastatin or any excipients in rosuvastatin calcium. ( 4 )
Description
General information about the drug product, including the proprietary and established name of the drug, the type of dosage form and route of administration to which the label applies, qualitative and quantitative ingredient information, the pharmacologic or therapeutic class of the drug, and the chemical name and structural formula of the drug.11 DESCRIPTION Rosuvastatin calcium, USP is a 3-hydroxy-3-methylglutaryl coenzyme A (HMG CoA)-reductase inhibitor. The chemical name for rosuvastatin calcium is bis [(E)-7-[4-(4-fluorophenyl)-6-isopropyl-2- [methyl (methylsulfonyl) amino] pyrimidin-5-yl] (3R, 5S)-3, 5-dihydroxyhept-6-enoic acid] calcium salt with the following structural formula: The molecular formula for rosuvastatin calcium, USP is (C 22 H 27 FN 3 O 6 S) 2 Ca and the molecular weight is 1001.14. Rosuvastatin calcium is a white amorphous powder that is sparingly soluble in water and methanol, and slightly soluble in ethanol. Rosuvastatin calcium is a hydrophilic compound with a partition coefficient (octanol/water) of 0.13 at pH of 7.0. Rosuvastatin tablets, USP for oral use contain rosuvastatin 5 mg, 10 mg, 20 mg, or 40 mg (equivalent to 5.2 mg, 10.4 mg, 20.8 mg, and 41.6 mg rosuvastatin calcium) and the following inactive ingredients: crospovidone, hypromellose, lactose monohydrate, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, pregelatinized starch, titanium dioxide and triacetin. Additionally, 10 mg, 20 mg and 40 mg tablets contain FD&C red No. 40/allura red AC aluminum lake, FD&C blue No. 2/indigo carmine aluminum lake and FD&C yellow No.6/sunset yellow FCF aluminum lake. Meets USP Dissolution Test 2. structure
Dosage and administration
Information about the drug product’s dosage and administration recommendations, including starting dose, dose range, titration regimens, and any other clinically sigificant information that affects dosing recommendations.2 DOSAGE AND ADMINISTRATION Take orally with or without food, at any time of day. ( 2.1 ) Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin calcium, and adjust dosage if necessary. ( 2.1 ) Adults: Recommended dosage range is 5 to 40 mg once daily. ( 2.1 ) Pediatric Patients with HeFH: Recommended dosage range is 5 to 10 mg once daily for patients aged 8 to less than 10 years of age, and 5 to 20 mg once daily for patients aged 10 years and older. ( 2.2 ) Pediatric Patients with HoFH: Recommended dosage is 20 mg once daily for patients aged 7 years and older. ( 2.2 ) Asian Patients: Initiate at 5 mg once daily. Consider risks and benefits of treatment if not adequately controlled at doses up to 20 mg once daily. ( 2.4 ) Patients with Severe Renal Impairment (not on hemodialysis): Initiate at 5 mg once daily; do not exceed 10 mg once daily. ( 2.5 , 5.1 , 8.6 ) See full prescribing information for rosuvastatin calcium dosage and administration modifications due to drug interactions. ( 2.6 ) 2.1 General Dosage and Administration Information Administer rosuvastatin calcium orally as a single dose at any time of day, with or without food. The tablet should be swallowed whole. Assess LDL-C when clinically appropriate, as early as 4 weeks after initiating rosuvastatin calcium, and adjust the dosage if necessary. If a dose is missed, advise patients not take an extra dose. Resume treatment with the next dose. 2.2 Recommended Dosage in Adult Patients The dosage range for rosuvastatin calcium is 5 to 40 mg orally once daily. The recommended dose of rosuvastatin calcium depends on a patient’s indication for usage, LDL-C, and individual risk for cardiovascular events. 2.3 Recommended Dosage in Pediatric Patients Dosage in Pediatric Patients 8 Years of Age and Older with HeFH The recommended dosage range is 5 mg to 10 mg orally once daily in patients aged 8 years to less than 10 years and 5 mg to 20 mg orally once daily in patients aged 10 years and older. Dosage in Pediatric Patients 7 Years of Age and Older with HoFH The recommended dosage is 20 mg orally once daily. 2.4 Dosing in Asian Patients Initiate rosuvastatin calcium at 5 mg once daily due to increased rosuvastatin plasma concentrations. Consider the risks and benefits of rosuvastatin calcium when treating Asian patients not adequately controlled at doses up to 20 mg once daily [ see Warnings and Precautions (5.1) , Use in Specific Populations (8.8) , and Clinical Pharmacology (12.3) ]. 2.5 Recommended Dosage in Patients with Renal Impairment In patients with severe renal impairment (CLcr less than 30 mL/min/1.73 m 2 ) not on hemodialysis, the recommended starting dosage is 5 mg once daily and should not exceed 10 mg once daily [ see Warnings and Precautions (5.1) and Use in Specific Populations (8.6) ]. There are no dosage adjustment recommendations for patients with mild and moderate renal impairment. 2.6 Dosage and Administration Modifications Due to Drug Interactions Rosuvastatin Calcium Dosage Modifications Due to Drug Interactions Table 1 displays dosage modifications for rosuvastatin calcium due to drug interactions [ see Warnings and Precautions (5.1) and Drug Interactions (7.1) ]. Table 1: Rosuvastatin calcium Dosage Modifications Due to Drug Interactions Concomitantly Used Drug Rosuvastatin calcium Dosage Modifications Cyclosporine Do not exceed 5 mg once daily. Teriflunomide Do not exceed 10 mg once daily. Enasidenib Do not exceed 10 mg once daily. Capmatinib Do not exceed 10 mg once daily. Fostamatinib Do not exceed 20 mg once daily. Febuxostat Do not exceed 20 mg once daily. Gemfibrozil Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily. Tafamidis Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily. Antiviral Medications Sofbuvir/velpatasvir/voxilaprevir Ledipasvir/sofosbuvir Concomitant use not recommended. Simeprevir Dasabuvir/ombitasvir/paritaprevir/ritonavir Elbasvir/Grazoprevir Sofosbuvir/Velpatasvir Glecaprevir/Pibrentasvir Atazanavir/Ritonavir Lopinavir/Ritonavir Initiate at 5 mg once daily. Do not exceed 10 mg once daily. Darolutamide Do not exceed 5 mg once daily. Regorafenib Do not exceed 10 mg once daily. Rosuvastatin Calcium Administration Modifications Due to Drug Interactions When taking rosuvastatin calcium with an aluminum and magnesium hydroxide combination antacid, administer rosuvastatin calcium at least 2 hours before the antacid [ see Drug Interactions (7.2) ].
| | |
| Cyclosporine | Do not exceed 5 mg once daily. |
| Teriflunomide | Do not exceed 10 mg once daily. |
| Enasidenib | Do not exceed 10 mg once daily. |
| Capmatinib | Do not exceed 10 mg once daily. |
| Fostamatinib | Do not exceed 20 mg once daily. |
| Febuxostat | Do not exceed 20 mg once daily. |
| Gemfibrozil | Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 10 mg once daily. |
| Tafamidis | Avoid concomitant use. If used concomitantly, initiate at 5 mg once daily and do not exceed 20 mg once daily. |
| Antiviral Medications | |
| Concomitant use not recommended. |
| Initiate at 5 mg once daily. Do not exceed 10 mg once daily. |
| Darolutamide | Do not exceed 5 mg once daily. |
| Regorafenib | Do not exceed 10 mg once daily. |
Dosage forms and strengths
Information about all available dosage forms and strengths for the drug product to which the labeling applies. This field may contain descriptions of product appearance.3 DOSAGE FORMS AND STRENGTHS Rosuvastatin tablets, USP: 5 mg: White, round shaped, biconvex film coated tablets debossed with "R5" on one side and plain on other side. 10 mg: Pink, round shaped, biconvex, film coated tablets debossed with "R10" on one side and plain on other side. 20 mg: Pink, round shaped, biconvex, film coated tablets debossed with "R20" on one side and plain on other side. 40 mg: Pink, oval shaped, biconvex, film coated tablets debossed with "R" on one side and "40" on other side. Tablets: 5 mg, 10 mg, 20 mg, and 40 mg of rosuvastatin. ( 3 )
Indications and usage
A statement of each of the drug products indications for use, such as for the treatment, prevention, mitigation, cure, or diagnosis of a disease or condition, or of a manifestation of a recognized disease or condition, or for the relief of symptoms associated with a recognized disease or condition. This field may also describe any relevant limitations of use.1 INDICATIONS AND USAGE Rosuvastatin tablets are indicated: To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to: o Reduce LDL-C in adults with primary hyperlipidemia. o Reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. o Reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia. Rosuvastatin Calcium is an HMG Co-A reductase inhibitor (statin) indicated: ( 1 ) To reduce the risk of stroke, myocardial infarction, and arterial revascularization procedures in adults without established coronary heart disease who are at increased risk of cardiovascular (CV) disease based on age, hsCRP ≥2 mg/L, and at least one additional CV risk factor. As an adjunct to diet to reduce LDL-C in adults with primary hyperlipidemia. As an adjunct to diet to reduce low-density lipoprotein cholesterol (LDL-C) and slow the progression of atherosclerosis in adults. As an adjunct to diet to reduce LDL-C in adults and pediatric patients aged 8 years and older with heterozygous familial hypercholesterolemia (HeFH). As an adjunct to other LDL-C-lowering therapies, or alone if such treatments are unavailable, to reduce LDL-C in adults and pediatric patients aged 7 years and older with homozygous familial hypercholesterolemia (HoFH). As an adjunct to diet for the treatment of adults with: o Primary dysbetalipoproteinemia. o Hypertriglyceridemia.
Spl product data elements
Usually a list of ingredients in a drug product.Rosuvastatin Calcium Rosuvastatin Calcium ROSUVASTATIN CALCIUM ROSUVASTATIN CROSPOVIDONE MAGNESIUM STEARATE MANNITOL MEGLUMINE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN FD&C RED NO. 40 FD&C YELLOW NO. 6 FD&C BLUE NO. 2 STARCH, CORN LACTOSE MONOHYDRATE R10 Rosuvastatin Calcium Rosuvastatin Calcium ROSUVASTATIN CALCIUM ROSUVASTATIN CROSPOVIDONE MAGNESIUM STEARATE MANNITOL MEGLUMINE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN FD&C RED NO. 40 FD&C YELLOW NO. 6 FD&C BLUE NO. 2 STARCH, CORN LACTOSE MONOHYDRATE R20 Rosuvastatin Calcium Rosuvastatin Calcium ROSUVASTATIN CALCIUM ROSUVASTATIN CROSPOVIDONE MAGNESIUM STEARATE MANNITOL MEGLUMINE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN FD&C RED NO. 40 FD&C YELLOW NO. 6 FD&C BLUE NO. 2 STARCH, CORN LACTOSE MONOHYDRATE R;40 Rosuvastatin Calcium Rosuvastatin Calcium ROSUVASTATIN CALCIUM ROSUVASTATIN CROSPOVIDONE MAGNESIUM STEARATE MANNITOL MEGLUMINE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN STARCH, CORN LACTOSE MONOHYDRATE R5 Rosuvastatin Calcium Rosuvastatin Calcium ROSUVASTATIN CALCIUM ROSUVASTATIN CROSPOVIDONE MAGNESIUM STEARATE MANNITOL MEGLUMINE CELLULOSE, MICROCRYSTALLINE HYPROMELLOSES TITANIUM DIOXIDE TRIACETIN STARCH, CORN LACTOSE MONOHYDRATE R5
Carcinogenesis and mutagenesis and impairment of fertility
Information about carcinogenic, mutagenic, or fertility impairment potential revealed by studies in animals. Information from human data about such potential is part of the warnings field.13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses. In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with Salmonella typhimurium and Escherichia coli , the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the in vivo mouse micronucleus test. In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.
Nonclinical toxicology
Information about toxicology in non-human subjects.13 NONCLINICAL TOXICOLOGY 13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility In a 104-week carcinogenicity study in rats at dose levels of 2, 20, 60, or 80 mg/kg/day by oral gavage, the incidence of uterine stromal polyps was significantly increased in females at 80 mg/kg/day at systemic exposure 20 times the human exposure at 40 mg/day based on AUC. Increased incidence of polyps was not seen at lower doses. In a 107-week carcinogenicity study in mice given 10, 60, or 200 mg/kg/day by oral gavage, an increased incidence of hepatocellular adenoma/carcinoma was observed at 200 mg/kg/day at systemic exposures 20 times the human exposure at 40 mg/day based on AUC. An increased incidence of hepatocellular tumors was not seen at lower doses. Rosuvastatin was not mutagenic or clastogenic with or without metabolic activation in the Ames test with Salmonella typhimurium and Escherichia coli , the mouse lymphoma assay, and the chromosomal aberration assay in Chinese hamster lung cells. Rosuvastatin was negative in the in vivo mouse micronucleus test. In rat fertility studies with oral gavage doses of 5, 15, 50 mg/kg/day, males were treated for 9 weeks prior to and throughout mating and females were treated 2 weeks prior to mating and throughout mating until gestation day 7. No adverse effect on fertility was observed at 50 mg/kg/day (systemic exposures up to 10 times the human exposure at 40 mg/day based on AUC). In testicles of dogs treated with rosuvastatin at 30 mg/kg/day for one month, spermatidic giant cells were seen. Spermatidic giant cells were observed in monkeys after 6-month treatment at 30 mg/kg/day in addition to vacuolation of seminiferous tubular epithelium. Exposures in the dog were 20 times and in the monkey 10 times the human exposure at 40 mg/day based on body surface area. Similar findings have been seen with other drugs in this class.
Package label principal display panel
The content of the principal display panel of the product package, usually including the product’s name, dosage forms, and other key information about the drug product.PACKAGE LABEL.PRINCIPAL DISPLAY PANEL 5 mg-Container-Label-90's Count 5 mg-Container-Label-500's Count 5 mg-Container-Label-1000's Count 10 mg-container-Label-90's count 10 mg-Container-Label-500's Count 10 mg-container-Label-1000's-count 20 mg-container-Label-90's-Count 20 mg-Container-Label-500's Count 20 mg-Container-Label-1000's-Count 40 mg-Container-Label-30's-Count 40 mg-Container-Label-90's-Count 40 mg-Container-Label-500's Count 40 mg-Container-Label-1000's-Count 5mg-90s 5mg-500s 5mg-1000s 10mg-90s 10mg-500s 10mg-1000s 20mg-90s 20mg-500s 20mg-1000s 40mg-30s 40mg-90s 40mg-500s 40mg-1000s
Recent major changes
A list of the section(s) that contain substantive changes that have been approved by FDA in the product labeling. The headings and subheadings, if appropriate, affected by the change are listed together with each section’s identifying number and the month and year on which the change was incorporated in the labeling.Dosage and Administration Modifications Due to Drug Interactions (2.6) 07/2023 Contraindications, Pregnancy and Lactation ( 4 ) Removed 01/2023 Warnings and Precautions ( 5.2 ) 01/2023 Warnings and Precautions, Concomitant Coumarin Anticoagulants ( 5.4 ) Removed 01/2023
Spl unclassified section
Information not classified as belonging to one of the other fields. Approximately 40% of labeling with effective_time between June 2009 and August 2014 have information in this field.PATIENT INFORMATION Rosuvastatin Tablets, USP (roe soo” va stat’ in) Read this Patient Information carefully before you start taking rosuvastatin tablets and each time you get a refill. If you have any questions about rosuvastatin tablets, ask your doctor. Only your doctor can determine if rosuvastatin tablets is right for you. What are Rosuvastatin tablets? Rosuvastatin tablets are a prescription medicine that contains a cholesterol-lowering medicine called rosuvastatin. Rosuvastatin tablets are used to: reduce the risk of stroke, heart attack, and the need for procedures to improve blood flow to the heart called arterial revascularization in adults who do not have known heart disease but do have certain additional risk factors. Rosuvastatin tablets are used along with diet to: lower the level of low-density lipoprotein (LDL) cholesterol or “bad” cholesterol in adults with primary hyperlipidemia. slow the buildup of fatty deposits (plaque) in the walls of blood vessels. treat adults and children 8 years of age and older with high blood cholesterol due to heterozygous familial hypercholesterolemia (an inherited condition that causes high levels of LDL). along with other cholesterol lowering treatments or alone if such treatments are unavailable in adults and children 7 years of age and older with homozygous familial hypercholesterolemia (an inherited condition that causes high levels of LDL). treat adults with a type of high cholesterol called primary dysbetalipoproteinemia (type III hyperlipoproteinemia). lower the level of fat in your blood (triglycerides) in adults with hypertriglyceridemia. The safety and effectiveness of rosuvastatin tablets has not been established in children younger than 8 years of age with heterozygous familial hypercholesterolemia or children younger than 7 years of age with homozygous familial hypercholesterolemia or in children with other types of hyperlipidemias (other than HeFH or HoFH). Who should not take rosuvastatin tablets? Do not take rosuvastatin tablets if you: have liver problems. are allergic to rosuvastatin calcium or any of the ingredients in rosuvastatin tablets. See the end of this leaflet for a complete list of ingredients in rosuvastatin tablets. Symptoms of allergic reactions include rash, itching, hives, and swelling. What should I tell my doctor before and while taking rosuvastatin tablets? Tell your doctor if you: have unexplained muscle aches or weakness. have or have had kidney problems. have or have had liver problems. drink more than 2 glasses of alcohol daily. have thyroid problems. are 65 years of age or older. are of Asian descent. are pregnant or think you may be pregnant, or are planning to become pregnant. If you become pregnant while taking rosuvastatin tablets, call your healthcare provider right away to discuss your rosuvastatin tablets treatment. are breastfeeding. Rosuvastatin can pass into your breast milk. Breastfeeding is not recommended while taking rosuvastatin tablets. Tell your doctor about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. Taking rosuvastatin tablets with certain other medicines may affect each other causing side effects. Rosuvastatin tablets may affect the way other medicines work, and other medicines may affect how rosuvastatin tablets works. Especially tell your doctor if you take: cyclosporine (a medicine for your immune system) gemfibrozil (a fibric acid medicine for lowering cholesterol) fostamatinib (a medicine used to treat low platelet counts) febuxostat (a medicine used to treat and prevent high blood levels of uric acid) teriflunomide (a medicine used to treat relapsing remitting multiple sclerosis) capmatinib (a medicine for the treatment of non-small cell lung cancer) tafamidis (used to treat cardiomyopathy [enlarged and thickened heart muscle]) darolutamide (a medicine for the treatment of prostate cancer) regorafenib (a medicine used to treat cancer of the colon and rectum) enasidenib (a medicine used to treat acute myeloid leukemia) anti-viral medicines including certain HIV or hepatitis C virus drugs such as: lopinavir, ritonavir, fosamprenavir, tipranavir, atazanavir, simeprevir combination of sofosbuvir/velpatasvir/voxilaprevir dasabuvir/ombitasvir/paritaprevir/ritonavir elbasvir/grazoprevir sofosbuvir/velpatasvir glecaprevir/pibrentasvir and all other combinations with ledipasvir including ledipasvir/sofosbuvir certain anti-fungal medicines (such as itraconazole, ketoconazole and fluconazole) coumarin anticoagulants (medicines that prevent blood clots, such as warfarin) niacin or nicotinic acid fibric acid derivatives (such as fenofibrate) colchicine (a medicine used to treat gout) Ask your doctor or pharmacist for a list of these medicines if you are not sure. Know the medicines you take. Keep a list of them to show your doctor and pharmacist when you get new medicine. How should I take rosuvastatin tablets? Take rosuvastatin tablets exactly as your doctor tells you to take it. Take rosuvastatin tablets, by mouth, 1 time each day. Swallow the tablet whole. Rosuvastatin tablets can be taken at any time of day, with or without food. Do not change your dose or stop rosuvastatin tablets without talking to your doctor, even if you are feeling well. Your doctor may do blood tests to check your cholesterol levels before and during your treatment with rosuvastatin tablets Your doctor may change your dose of rosuvastatin tablets if needed. Your doctor may start you on a cholesterol lowering diet before giving you rosuvastatin tablets. Stay on this diet when you take rosuvastatin tablets. Wait at least 2 hours after taking rosuvastatin tablets to take an antacid that contains a combination of aluminum and magnesium hydroxide. If you miss a dose of rosuvastatin tablets, take your next dose at your normal scheduled time. Do not take an extra dose of rosuvastatin tablets. If you take too much rosuvastatin tablets or overdose, call your doctor or go to the nearest hospital emergency room right away. What are the possible side effects of rosuvastatin tablets? Rosuvastatin tablets may cause serious side effects, including: Muscle pain, tenderness and weakness (myopathy). Muscle problems, including muscle breakdown, can be serious in some people and rarely cause kidney damage that can lead to death. Tell your doctor right away if: you have unexplained muscle pain, tenderness, or weakness, especially if you have a fever or feel more tired than usual, while you take rosuvastatin tablets. you have muscle problems that do not go away even after your doctor has told you to stop taking rosuvastatin tablets. Your doctor may do further tests to diagnose the cause of your muscle problems. Your chances of getting muscle problems are higher if you: are taking certain other medicines while you take rosuvastatin tablets are 65 years of age or older have thyroid problems (hypothyroidism) that are not controlled have kidney problems are taking higher doses of rosuvastatin tablets Liver problems. Your doctor should do blood tests to check your liver before you start taking rosuvastatin tablets and if you have symptoms of liver problems while you take rosuvastatin tablets. Call your doctor right away if you have any of the following symptoms of liver problems: feel unusually tired or weak loss of appetite upper belly pain dark urine yellowing of your skin or the whites of your eyes Protein and blood in the urine. Rosuvastatin tablets may cause you to have protein and blood in your urine. If you develop protein or blood in your urine, your doctor may decrease your dose of rosuvastatin tablets. Increase in blood sugar (glucose) levels . Rosuvastatin tablets may cause an increase in your blood sugar levels. The most common side effects may include headache, muscle aches and pains, abdominal pain, weakness, and nausea. Tell your doctor if you have any side effect that bothers you or that does not go away. For more information, ask your doctor or pharmacist. Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. How should I store rosuvastatin tablets? Store rosuvastatin tablets at room temperature, between 68°F to 77°F (20°C to 25°C) and in a dry place. Safely throw away medicine that is out of date or no longer needed. Keep rosuvastatin tablets and all medicines out of the reach of children. General Information about the safe and effective use of rosuvastatin tablets Medicines are sometimes prescribed for purposes other than those listed in a Patient Information leaflet. Do not use rosuvastatin tablets for a condition for which it was not prescribed. Do not give rosuvastatin tablets to other people, even if they have the same medical condition you have. It may harm them. You can ask your pharmacist or doctor for information about rosuvastatin tablets that is written for health professionals. What are the Ingredients in rosuvastatin tablets? Active Ingredient: rosuvastatin as rosuvastatin calcium Inactive Ingredients: crospovidone, hypromellose, lactose monohydrate, magnesium stearate, mannitol, meglumine, microcrystalline cellulose, pregelatinized starch, titanium dioxide and triacetin. Additionally, 10 mg, 20 mg and 40 mg tablets contain FD&C red No. 40/allura red AC aluminum lake, FD&C blue No. 2/indigo carmine aluminum lake and FD&C yellow No.6/sunset yellow FCF aluminum lake. For more information, go to www.novadozpharma.com or call 1-855-668-2369. This Patient Information has been approved by the U.S. Food and Drug Administration Manufactured by: MSN Laboratories Private Limited Telangana – 509 228, INDIA Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854-3714 Issued on: September 2023
| Rosuvastatin Tablets, USP (roe soo” va stat’ in) |
| Read this Patient Information carefully before you start taking rosuvastatin tablets and each time you get a refill. If you have any questions about rosuvastatin tablets, ask your doctor. Only your doctor can determine if rosuvastatin tablets is right for you. |
|
|
|
|
|
|
Rosuvastatin Calcium: Information for patients
Information necessary for patients to use the drug safely and effectively, such as precautions concerning driving or the concomitant use of other substances that may have harmful additive effects.17 PATIENT COUNSELING INFORMATION Advise the patient to read the FDA-approved patient labeling (Patient Information). Myopathy and Rhabdomyolysis Advise patients that rosuvastatin calcium may cause myopathy and rhabdomyolysis. Inform patients that the risk is also increased when taking certain types of medication and they should discuss all medication, both prescription and over the counter, with their healthcare provider. Instruct patients to promptly report any unexplained muscle pain, tenderness or weakness particularly if accompanied by malaise or fever [ see Warnings and Precautions (5.1) , and Drug Interactions (7.1) ]. Hepatic Dysfunction Inform patients that rosuvastatin calcium may cause liver enzyme elevations and possibly liver failure. Advise patients to promptly report fatigue, anorexia, right upper abdominal discomfort, dark urine or jaundice [ see Warnings and Precautions (5.3) ]. Increases in HbA1c and Fasting Serum Glucose Levels Inform patients that increases in HbA1c and fasting serum glucose levels may occur with rosuvastatin calcium. Encourage patients to optimize lifestyle measures, including regular exercise, maintaining a healthy body weight, and making healthy food choices [ see Warnings and Precautions (5.5) ]. Pregnancy Advise pregnant patients and patients who can become pregnant of the potential risk to a fetus. Advise patients to inform their healthcare provider of a known or suspected pregnancy to discuss if rosuvastatin calcium should be discontinued [ see Use in Specific Populations (8.1) ]. Lactation Advise patients that breastfeeding during treatment with rosuvastatin calcium is not recommended [ see Use in Specific Populations (8.2) ]. Concomitant Use of Antacids When taking rosuvastatin calcium with an aluminum and magnesium hydroxide combination antacid, the antacid should be taken at least 2 hours after rosuvastatin calcium administration [see Drug Interactions (7.2) ]. Missed Doses If a dose is missed, advise patients not take an extra dose. Just resume the usual schedule [see General Dosage and Administration Information (2.1) ]. Manufactured by: MSN Laboratories Private Limited Telangana – 509 228, INDIA Distributed by: Novadoz Pharmaceuticals LLC Piscataway, NJ 08854-3714 Issued on: September 2023
Clinical studies
This field may contain references to clinical studies in place of detailed discussion in other sections of the labeling.14 CLINICAL STUDIES Primary Prevention of Cardiovascular Disease In the Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER) study, the effect of rosuvastatin calcium on the occurrence of major cardiovascular (CV) disease events was assessed in 17,802 men (≥50 years) and women (≥60 years) who had no clinically evident cardiovascular disease, LDL-C levels <130 mg/dL and hsCRP levels ≥2 mg/L. The study population had an estimated baseline coronary heart disease risk of 11.6% over 10 years based on the Framingham risk criteria and included a high percentage of patients with additional risk factors such as hypertension (58%), low HDL-C levels (23%), cigarette smoking (16%), or a family history of premature CHD (12%). Patients had a median baseline LDL-C of 108 mg/dL and hsCRP of 4.3 mg/L. Patients were randomly assigned to placebo (n=8901) or rosuvastatin calcium 20 mg once daily (n=8901) and were followed for a mean duration of 2 years. The JUPITER study was stopped early by the Data Safety Monitoring Board due to meeting predefined stopping rules for efficacy in rosuvastatin calcium-treated subjects. The primary end point was a composite end point consisting of the time-to-first occurrence of any of the following major CV events: CV death, nonfatal myocardial infarction, nonfatal stroke, hospitalization for unstable angina or an arterial revascularization procedure. Rosuvastatin calcium significantly reduced the risk of major CV events (252 events in the placebo group vs. 142 events in the rosuvastatin group) with a statistically significant (p<0.001) relative risk reduction of 44% and absolute risk reduction of 1.2% (see Figure 1). The risk reduction for the primary end point was consistent across the following predefined subgroups: age, sex, race, smoking status, family history of premature CHD, body mass index, LDL-C, HDL-C, and hsCRP levels. Figure 1. Time to First Occurrence of Major Cardiovascular Events in JUPITER The individual components of the primary end point are presented in Figure 3. Rosuvastatin calcium significantly reduced the risk of nonfatal myocardial infarction, nonfatal stroke, and arterial revascularization procedures. There were no significant treatment differences between the rosuvastatin calcium and placebo groups for death due to cardiovascular causes or hospitalizations for unstable angina. Rosuvastatin calcium significantly reduced the risk of myocardial infarction (6 fatal events and 62 nonfatal events in placebo-treated subjects vs. 9 fatal events and 22 nonfatal events in rosuvastatin calcium-treated subjects) and the risk of stroke (6 fatal events and 58 nonfatal events in placebo-treated subjects vs. 3 fatal events and 30 nonfatal events in rosuvastatin calcium -treated subjects). In a post-hoc subgroup analysis of JUPITER subjects (rosuvastatin=725, placebo=680) with a hsCRP ≥2 mg/L and no other traditional risk factors (smoking, BP ≥140/90 or taking antihypertensives, low HDL-C) other than age, after adjustment for high HDL-C, there was no significant treatment benefit with rosuvastatin calcium treatment. Figure 2. Major CV Events by Treatment Group in JUPITER At one year, rosuvastatin calcium increased HDL-C and reduced LDL-C, hsCRP, total cholesterol and serum triglyceride levels (p<0.001 for all versus placebo). Primary Hyperlipidemia in Adults Rosuvastatin calcium reduces Total-C, LDL-C, ApoB, non-HDL-C, and TG, and increases HDL-C, in adult patients with hyperlipidemia and mixed dyslipidemia. In a multicenter, double-blind, placebo-controlled study in patients with hyperlipidemia, rosuvastatin calcium given as a single daily dose (5 to 40 mg) for 6 weeks significantly reduced Total-C, LDL-C, non-HDL-C, and ApoB, across the dose range (Table 10). Table 10: Lipid-modifying Effect of Rosuvastatin calcium in Adult Patients with Hyperlipidemia (Adjusted Mean % Change from Baseline at Week 6) Dose N Total-C LDL-C Non-HDL-C ApoB TG HDL-C Placebo 13 -5 -7 -7 -3 -3 3 Rosuvastatin calcium 5 mg 17 -33 -45 -44 -38 -35 13 Rosuvastatin calcium 10 mg 17 -36 -52 -48 -42 -10 14 Rosuvastatin calcium 20 mg 17 -40 -55 -51 -46 -23 8 Rosuvastatin calcium 40 mg 18 -46 -63 -60 -54 -28 10 Rosuvastatin calcium was compared with the statins (atorvastatin, simvastatin, and pravastatin) in a multicenter, open-label, dose-ranging study of 2240 patients with hyperlipidemia or mixed dyslipidemia. After randomization, patients were treated for 6 weeks with a single daily dose of either rosuvastatin calcium, atorvastatin, simvastatin, or pravastatin (Figure 3 and Table 11). Figure 3. Percent LDL-C Change by Dose of Rosuvastatin calcium, Atorvastatin, Simvastatin, and Pravastatin at Week 6 in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia Box plots are a representation of the 25th, 50th, and 75th percentile values, with whiskers representing the 10th and 90th percentile values. Mean baseline LDL-C: 189 mg/dL Table 11: Percent Change in LDL-C by Dose of Rosuvastatin calcium, Atorvastatin, Simvastatin, and Pravastatin From Baseline to Week 6 (LS Mean 1 ) in Adult Patients with Hyperlipidemia or Mixed Dyslipidemia (Sample Sizes Ranging from 156–167 Patients Per Group) Treatment Daily Dose Treatment 10 mg 20 mg 40 mg 80 mg Rosuvastatin calcium -46 2 -52 3 -55 4 --- Atorvastatin -37 -43 -48 -51 Simvastatin -28 -35 -39 -46 Pravastatin -20 -24 -30 --- 1 Corresponding standard errors are approximately 1.00. 2 Rosuvastatin calcium 10 mg reduced LDL-C significantly more than atorvastatin 10 mg; pravastatin 10 mg, 20 mg, and 40 mg; simvastatin 10 mg, 20 mg, and 40 mg. (p<0.002) 3 Rosuvastatin calcium 20 mg reduced LDL-C significantly more than atorvastatin 20 mg and 40 mg; pravastatin 20 mg and 40 mg; simvastatin 20 mg, 40 mg, and 80 mg. (p<0.002) 4 Rosuvastatin calcium 40 mg reduced LDL-C significantly more than atorvastatin 40 mg; pravastatin 40 mg; simvastatin 40 mg, and 80 mg. (p<0.002) Slowing of the Progression of Atherosclerosis In the Measuring Effects on Intima Media Thickness: an Evaluation Of Rosuvastatin 40 mg (METEOR) study, the effect of therapy with rosuvastatin calcium on carotid atherosclerosis was assessed by B-mode ultrasonography in patients with elevated LDL-C, at low risk (Framingham risk <10% over ten years) for symptomatic coronary artery disease and with subclinical atherosclerosis as evidenced by carotid intimal-medial thickness (cIMT). In this double-blind, placebo-controlled clinical study 984 adult patients were randomized (of whom 876 were analyzed) in a 5:2 ratio to rosuvastatin calcium 40 mg or placebo once daily. Ultrasonograms of the carotid walls were used to determine the annualized rate of change per patient from baseline to two years in mean maximum cIMT of 12 measured segments. The estimated difference in the rate of change in the maximum cIMT analyzed over all 12 carotid artery sites between patients treated with rosuvastatin calcium and placebo-treated patients was -0.0145 mm/year (95% CI –0.0196, – 0.0093; p<0.0001). The annualized rate of change from baseline for the placebo group was +0.0131 mm/year (p<0.0001). The annualized rate of change from baseline for the group treated with rosuvastatin calcium was -0.0014 mm/year (p=0.32). At an individual patient level in the group treated with rosuvastatin calcium, 52.1% of patients demonstrated an absence of disease progression (defined as a negative annualized rate of change), compared to 37.7% of patients in the placebo group. HeFH in Adults In a study of adult patients with HeFH (baseline mean LDL of 291 mg/dL), patients were randomized to rosuvastatin calcium 20 mg or atorvastatin 20 mg. The dose was increased at 6-week intervals. Significant LDL-C reductions from baseline were seen at each dose in both treatment groups (Table 12). Table 12: LDL-C Percent Change from Baseline Rosuvastatin calcium (n=435) LS Mean 1 (95% CI) Atorvastatin (n=187) LS Mean 1 (95% CI) Week 6 20 mg -47% (-49%, -46%) -38% (-40%, -36%) Week 12 40 mg -55% (-57%, -54%) -47% (-49%, -45%) Week 18 80 mg NA -52% (-54%, -50%) 1 LS Means are least square means adjusted for baseline LDL-C HeFH in Pediatric Patients In a double-blind, randomized, multicenter, placebo-controlled, 12-week study, 176 (97 male and 79 female) children and adolescents with heterozygous familial hypercholesterolemia were randomized to rosuvastatin 5 mg, 10 mg or 20 mg or placebo daily. Patients ranged in age from 10 to 17 years (median age of 14 years) with approximately 30% of the patients 10 to 13 years and approximately 17%, 18%, 40%, and 25% at Tanner stages II, III, IV, and V, respectively. Females were at least 1 year postmenarche. Mean LDL-C at baseline was 233 mg/dL (range of 129 to 399). The 12-week double-blind phase was followed by a 40 week open label dose-titration phase, where all patients (n=173) received 5 mg, 10 mg or 20 mg rosuvastatin daily. Rosuvastatin significantly reduced LDL-C (primary end point), total cholesterol and ApoB levels at each dose compared to placebo. Results are shown in Table 13 below. Table 13: Lipid-Modifying Effects of Rosuvastatin calcium in Pediatric Patients 10 to 17 years of Age with Heterozygous Familial Hypercholesterolemia (Least-Squares Mean Percent Change from Baseline To Week 12) Dose (mg) N LDL-C HDL-C Total-C TG 1 ApoB Placebo 46 -1% +7% 0% -7% -2% 5 42 -38% +4% 2 -30% -13% 2 -32% 10 44 -45% +11% 2 -34% -15% 2 -38% 20 44 -50% +9% 2 -39% 16% 2 -41% 1 Median percent change 2 Difference from placebo not statistically significant Rosuvastatin was also studied in a two-year open-label, uncontrolled, titration-to-goal trial that included 175 children and adolescents with heterozygous familial hypercholesterolemia who were 8 to 17 years old (79 boys and 96 girls). All patients had a documented genetic defect in the LDL receptor or in ApoB. Approximately 89% were White, 7% were Asian, 1% were Black, and fewer than 1% were Hispanic. Mean LDL-C at baseline was 236 mg/dL. Fifty-eight (33%) patients were prepubertal at baseline. The starting rosuvastatin dosage for all children and adolescents was 5 mg once daily. Children 8 to less than 10 years of age (n=41 at baseline) could titrate to a maximum dosage of 10 mg once daily, and children and adolescents 10 to 17 years of age could titrate to a maximum dosage of 20 mg once daily. The reductions in LDL-C from baseline were generally consistent across age groups within the trial as well as with previous experience in both adult and pediatric controlled trials. HoFH in Adult and Pediatric Patients In an open-label, forced-titration study, HoFH patients (n=40, 8-63 years) were evaluated for their response to rosuvastatin calcium 20 to 40 mg titrated at a 6-week interval. In the overall population, the mean LDL-C reduction from baseline was 22%. About one-third of the patients benefited from increasing their dose from 20 mg to 40 mg with further LDL-C lowering of greater than 6%. In the 27 patients with at least a 15% reduction in LDL-C, the mean LDL-C reduction was 30% (median 28% reduction). Among 13 patients with an LDL-C reduction of <15%, 3 had no change or an increase in LDL-C. Reductions in LDL-C of 15% or greater were observed in 3 of 5 patients with known receptor negative status. HoFH in Pediatric Patients Rosuvastatin calcium was studied in a randomized, double-blind, placebo-controlled, multicenter, cross¬over study in 14 pediatric patients with HoFH. The study included a 4-week dietary lead-in phase during which patients received rosuvastatin calcium 10 mg daily, a cross-over phase that included two 6-week treatment periods with either rosuvastatin calcium 20 mg or placebo in random order, followed by a 12-week open-label phase during which all patients received rosuvastatin calcium 20 mg. Patients ranged in age from 7 to 15 years of age (median 11 years), 50% were male, 71% were White, 21% were Asian, 7% were Black, and no patients were of Hispanic ethnicity. Fifty percent were on apheresis therapy and 57% were taking ezetimibe. Patients who entered the study on apheresis therapy or ezetimibe continued the treatment throughout the entire study. Mean LDL-C at baseline was 416 mg/dL (range 152 to 716 mg/dL). A total of 13 patients completed both treatment periods of the randomized cross-over phase; one patient withdrew consent due to inability to have blood drawn during the cross-over phase. Rosuvastatin calcium 20 mg significantly reduced LDL-C, total cholesterol, ApoB, and non-HDL-C compared to placebo (Table 14). Table 14: Lipid-modifying Effects of Rosuvastatin calcium in Pediatric Patients 7 to 15 years of Age with Homozygous Familial Hypercholesterolemia After 6 Weeks Placebo (N=13) Rosuvastatin calcium 20 mg (N=13) Percent difference (95% CI) LDL-C (mg/dL) 481 396 -22.3% (-33.5, -9.1) 1 Total-C (mg/dL) 539 448 -20.1% (-29.7, -9.1) 2 Non-HDL-C (mg/dL) 505 412 -22.9% (-33.7, -10.3) 2 ApoB (mg/dL) 268 235 -17.1% (-29.2, -2.9) 3 %Difference estimates are based on transformations of the estimated mean difference in log LDL measurements between rosuvastatin calcium and placebo using a mixed model adjusted for study period 1 p=0.005, 2 p=0.003, 3 p=0.024 Primary Dysbetalipoproteinemia in Adults In a randomized, multicenter, double-blind crossover study, 32 adult patients (27 with є2/є2 and 4 with apo E mutation [Arg145Cys] with primary dysbetalipoproteinemia entered a 6-week dietary lead-in period on the NCEP Therapeutic Lifestyle Change (TLC) diet. Following dietary lead-in, patients were randomized to a sequence of treatments for 6 weeks each: rosuvastatin 10 mg followed by rosuvastatin 20 mg or rosuvastatin 20 mg followed by rosuvastatin 10 mg. Rosuvastatin calcium reduced non-HDL-C (primary end point) and circulating remnant lipoprotein levels. Results are shown in the table below. Table 15: Lipid-modifying Effects of Rosuvastatin calcium 10 mg and 20 mg in Adult Patients with Primary Dysbetalipoproteinemia (Type III hyperlipoproteinemia) After Six Weeks by Median Percent Change (95% CI) from Baseline (N=32) Median at Baseline (mg/dL) Median percent change from baseline (95% CI) rosuvastatin calcium 10 mg Median percent change from baseline (95% CI) rosuvastatin calcium 20 mg Total-C 342.5 -43.3 (-46.9, -37.5) -47.6 (-51.6,-42.8) Triglycerides 503.5 -40.1 (-44.9, -33.6) -43.0 (-52.5, -33.1) Non-HDL-C 294.5 -48.2 (-56.7, -45.6) -56.4 (-61.4, -48.5) VLDL-C + IDL-C 209.5 -46.8 (-53.7, -39.4) -56.2 (-67.7, -43.7) LDL-C 112.5 -54.4 (-59.1, -47.3) -57.3 (-59.4, -52.1) HDL-C 35.5 10.2 (1.9, 12.3) 11.2 (8.3, 20.5) RLP-C 82.0 -56.4 (-67.1, -49.0) -64.9 (-74.0, -56.6) Apo-E 16.0 -42.9 (-46.3, -33.3) -42.5 (-47.1, -35.6) Hypertriglyceridemia in Adults In a double-blind, placebo-controlled study in adult patients with baseline TG levels from 273 to 817 mg/dL, rosuvastatin calcium given as a single daily dose (5 to 40 mg) over 6 weeks significantly reduced serum TG levels (Table 16). Table 16: Lipid-Modifying Effect of Rosuvastatin calcium in Adult Patients with Primary Hypertriglyceridemia After Six Weeks by Median (Min, Max) Percent Change from Baseline to Week 6 Dose Placebo (n=26) Rosuvastatin calcium 5 mg (n=25) Rosuvastatin calcium 10 mg (n=23) Rosuvastatin calcium 20 mg (n=27) Rosuvastatin calcium 40 mg (n=25) Triglycerides 1 (-40, 72) -21 (-58, 38) -37 (-65, 5) -37 (-72, 11) -43 (-80, -7) Non-HDL-C 2 (-13, 19) -29 (-43, -8) -49 (-59, -20) -43 (-74, 12) -51 (-62, -6) Total-C 1 (-13, 17) -24 (-40, -4) -40 (-51, -14) -34 (-61, -11) -40 (-51, -4) LDL-C 5 (-30, 52) -28 (-71, 2) -45 (-59, 7) -31 (-66, 34) -43 (-61, -3) HDL-C -3 (-25, 18) 3 (-38, 33) 8 (-8, 24) 22 (-5, 50) 17 (-14, 63) rosuvastatin-fig-03 rosuvastatin-fig-01 rosuvastatin-fig-02
| | | | | | | | |
| Placebo | 13 | -5 | -7 | -7 | -3 | -3 | 3 |
| Rosuvastatin calcium 5 mg | 17 | -33 | -45 | -44 | -38 | -35 | 13 |
| Rosuvastatin calcium 10 mg | 17 | -36 | -52 | -48 | -42 | -10 | 14 |
| Rosuvastatin calcium 20 mg | 17 | -40 | -55 | -51 | -46 | -23 | 8 |
| Rosuvastatin calcium 40 mg | 18 | -46 | -63 | -60 | -54 | -28 | 10 |
| | ||||
| | | | | |
| Rosuvastatin calcium | -462 | -523 | -554 | --- |
| Atorvastatin | -37 | -43 | -48 | -51 |
| Simvastatin | -28 | -35 | -39 | -46 |
| Pravastatin | -20 | -24 | -30 | --- |
| | | ||
| Week 6 | 20 mg | -47% (-49%, -46%) | -38% (-40%, -36%) |
| Week 12 | 40 mg | -55% (-57%, -54%) | -47% (-49%, -45%) |
| Week 18 | 80 mg | NA | -52% (-54%, -50%) |
| | | | | | | |
| Placebo | 46 | -1% | +7% | 0% | -7% | -2% |
| 5 | 42 | -38% | +4% | -30% | -13% | -32% |
| 10 | 44 | -45% | +11% | -34% | -15% | -38% |
| 20 | 44 | -50% | +9% | -39% | 16% | -41% |
| | | | ||
| LDL-C (mg/dL) | 481 | 396 | -22.3% (-33.5, -9.1)1 | |
| Total-C (mg/dL) | 539 | 448 | -20.1% (-29.7, -9.1)2 | |
| Non-HDL-C (mg/dL) | 505 | 412 | -22.9% (-33.7, -10.3)2 | |
| ApoB (mg/dL) | 268 | 235 | -17.1% (-29.2, -2.9)3 | |
| | | | |
| Total-C | 342.5 | -43.3 (-46.9, -37.5) | -47.6 (-51.6,-42.8) |
| Triglycerides | 503.5 | -40.1 (-44.9, -33.6) | -43.0 (-52.5, -33.1) |
| Non-HDL-C | 294.5 | -48.2 (-56.7, -45.6) | -56.4 (-61.4, -48.5) |
| VLDL-C + IDL-C | 209.5 | -46.8 (-53.7, -39.4) | -56.2 (-67.7, -43.7) |
| LDL-C | 112.5 | -54.4 (-59.1, -47.3) | -57.3 (-59.4, -52.1) |
| HDL-C | 35.5 | 10.2 (1.9, 12.3) | 11.2 (8.3, 20.5) |
| RLP-C | 82.0 | -56.4 (-67.1, -49.0) | -64.9 (-74.0, -56.6) |
| Apo-E | 16.0 | -42.9 (-46.3, -33.3) | -42.5 (-47.1, -35.6) |
| | | | | | |
| Triglycerides | 1 (-40, 72) | -21 (-58, 38) | -37 (-65, 5) | -37 (-72, 11) | -43 (-80, -7) |
| Non-HDL-C | 2 (-13, 19) | -29 (-43, -8) | -49 (-59, -20) | -43 (-74, 12) | -51 (-62, -6) |
| Total-C | 1 (-13, 17) | -24 (-40, -4) | -40 (-51, -14) | -34 (-61, -11) | -40 (-51, -4) |
| LDL-C | 5 (-30, 52) | -28 (-71, 2) | -45 (-59, 7) | -31 (-66, 34) | -43 (-61, -3) |
| HDL-C | -3 (-25, 18) | 3 (-38, 33) | 8 (-8, 24) | 22 (-5, 50) | 17 (-14, 63) |
Geriatric use
Information about any limitations on any geriatric indications, needs for specific monitoring, hazards associated with use of the drug in the geriatric population.8.5 Geriatric Use Of the total number of rosuvastatin calcium-treated patients in clinical studies, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Advanced age (≥65 years) is a risk factor for rosuvastatin calcium-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving rosuvastatin calcium for the increased risk of myopathy [ see Warnings and Precautions (5.1) ].
Pediatric use
Information about any limitations on any pediatric indications, needs for specific monitoring, hazards associated with use of the drug in any subsets of the pediatric population (such as neonates, infants, children, or adolescents), differences between pediatric and adult responses to the drug, and other information related to the safe and effective pediatric use of the drug.8.4 Pediatric Use The safety and effectiveness of rosuvastatin calcium as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use of rosuvastatin calcium for this indication is based on one 12-week controlled trial with a 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2-year open-label, uncontrolled trial in 175 pediatric patients 8 years of age and older with HeFH [ see Clinical Studies (14) ]. In the 1-year trial with a 12-week controlled phase, there was no detectable effect of rosuvastatin calcium on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years. The safety and effectiveness of rosuvastatin calcium as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 7 years of age and older with HoFH. Use of rosuvastatin calcium for this indication is based on a randomized, placebo-controlled, cross-over study in 14 pediatric patients 7 years of age and older with HoFH [ see Clinical Studies (14) ]. The safety and effectiveness of rosuvastatin calcium have not been established in pediatric patients younger than 8 years of age with HeFH, younger than 7 years of age with HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH).
Pregnancy
Information about effects the drug may have on pregnant women or on a fetus. This field may be ommitted if the drug is not absorbed systemically and the drug is not known to have a potential for indirect harm to the fetus. It may contain information about the established pregnancy category classification for the drug. (That information is nominally listed in the teratogenic_effects field, but may be listed here instead.)8.1 Pregnancy Risk Summary Discontinue rosuvastatin calcium when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Rosuvastatin calcium decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, rosuvastatin calcium may cause fetal harm when administered to pregnant patients based on the mechanism of action [ see Clinical Pharmacology (12.1) ]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with rosuvastatin calcium use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m 2 ), respectively (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. Animal Data In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC). In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area). In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area). Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after a single oral gavage dose of 1 mg/kg on gestation day 18.
Use in specific populations
Information about use of the drug by patients in specific populations, including pregnant women and nursing mothers, pediatric patients, and geriatric patients.8 USE IN SPECIFIC POPULATIONS Pregnancy: May cause fetal harm. ( 8.1 ) Lactation: Breastfeeding not recommended during treatment with rosuvastatin calcium. ( 8.2 ) 8.1 Pregnancy Risk Summary Discontinue rosuvastatin calcium when pregnancy is recognized. Alternatively, consider the ongoing therapeutic needs of the individual patient. Rosuvastatin calcium decreases synthesis of cholesterol and possibly other biologically active substances derived from cholesterol; therefore, rosuvastatin calcium may cause fetal harm when administered to pregnant patients based on the mechanism of action [ see Clinical Pharmacology (12.1) ]. In addition, treatment of hyperlipidemia is not generally necessary during pregnancy. Atherosclerosis is a chronic process and the discontinuation of lipid-lowering drugs during pregnancy should have little impact on the outcome of long-term therapy of primary hyperlipidemia for most patients. Available data from case series and prospective and retrospective observational cohort studies over decades of use with statins in pregnant women have not identified a drug-associated risk of major congenital malformations. Published data from prospective and retrospective observational cohort studies with rosuvastatin calcium use in pregnant women are insufficient to determine if there is a drug-associated risk of miscarriage (see Data). In animal reproduction studies, no adverse developmental effects were observed in pregnant rats or rabbits orally administered rosuvastatin during the period of organogenesis at doses that resulted in systemic exposures equivalent to human exposures at the maximum recommended human dose (MRHD) of 40 mg/day, based on AUC and body surface area (mg/m 2 ), respectively (see Data). The estimated background risk of major birth defects and miscarriage for the indicated population is unknown. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively. Data Human Data A Medicaid cohort linkage study of 1152 statin-exposed pregnant women compared to 886,996 controls did not find a significant teratogenic effect from maternal use of statins in the first trimester of pregnancy, after adjusting for potential confounders – including maternal age, diabetes mellitus, hypertension, obesity, and alcohol and tobacco use – using propensity score-based methods. The relative risk of congenital malformations between the group with statin use and the group with no statin use in the first trimester was 1.07 (95% confidence interval 0.85 to 1.37) after controlling for confounders, particularly pre-existing diabetes mellitus. There were also no statistically significant increases in any of the organ-specific malformations assessed after accounting for confounders. In the majority of pregnancies, statin treatment was initiated prior to pregnancy and was discontinued at some point in the first trimester when pregnancy was identified. Study limitations include reliance on physician coding to define the presence of a malformation, lack of control for certain confounders such as body mass index, use of prescription dispensing as verification for the use of a statin, and lack of information on non-live births. Animal Data In female rats given 5, 15 and 50 mg/kg/day before mating and continuing through to gestation day 7 resulted in decreased fetal body weight (female pups) and delayed ossification at 50 mg/kg/day (10 times the human exposure at the MRHD dose of 40 mg/day based on AUC). In pregnant rats given 2, 10 and 50 mg/kg/day of rosuvastatin from gestation day 7 through lactation day 21 (weaning), decreased pup survival occurred at 50 mg/kg/day (dose equivalent to 12 times the MRHD of 40 mg/day based body surface area). In pregnant rabbits given 0.3, 1, and 3 mg/kg/day of rosuvastatin from gestation day 6 to day 18, decreased fetal viability and maternal mortality was observed at 3 mg/kg/day (dose equivalent to the MRHD of 40 mg/day based on body surface area). Rosuvastatin crosses the placenta in rats and rabbits and is found in fetal tissue and amniotic fluid at 3% and 20%, respectively, of the maternal plasma concentration following a single 25 mg/kg oral gavage dose on gestation day 16 in rats. In rabbits, fetal tissue distribution was 25% of maternal plasma concentration after a single oral gavage dose of 1 mg/kg on gestation day 18. 8.2 Lactation Risk Summary Limited data from case reports in published literature indicate that rosuvastatin calcium is present in human milk. There is no available information on the effects of the drug on the breastfed infant or the effects of the drug on milk production. Statins, including rosuvastatin calcium, decrease cholesterol synthesis and possibly the synthesis of other biologically active substances derived from cholesterol and may cause harm to the breastfed infant. Because of the potential for serious adverse reactions in a breastfed infant, based on the mechanism of action, advise patients that breastfeeding is not recommended during treatment with rosuvastatin calcium [ see Use in Specific Populations (8.1) and Clinical Pharmacology (12.1) ]. 8.4 Pediatric Use The safety and effectiveness of rosuvastatin calcium as an adjunct to diet to reduce LDL-C have been established in pediatric patients 8 years of age and older with HeFH. Use of rosuvastatin calcium for this indication is based on one 12-week controlled trial with a 40-week open-label extension period in 176 pediatric patients 10 years of age and older with HeFH and one 2-year open-label, uncontrolled trial in 175 pediatric patients 8 years of age and older with HeFH [ see Clinical Studies (14) ]. In the 1-year trial with a 12-week controlled phase, there was no detectable effect of rosuvastatin calcium on growth, weight, BMI (body mass index), or sexual maturation in patients aged 10 to 17 years. The safety and effectiveness of rosuvastatin calcium as an adjunct to other LDL-C-lowering therapies to reduce LDL-C have been established pediatric patients 7 years of age and older with HoFH. Use of rosuvastatin calcium for this indication is based on a randomized, placebo-controlled, cross-over study in 14 pediatric patients 7 years of age and older with HoFH [ see Clinical Studies (14) ]. The safety and effectiveness of rosuvastatin calcium have not been established in pediatric patients younger than 8 years of age with HeFH, younger than 7 years of age with HoFH, or in pediatric patients with other types of hyperlipidemia (other than HeFH or HoFH). 8.5 Geriatric Use Of the total number of rosuvastatin calcium-treated patients in clinical studies, 3159 (31%) were 65 years and older, and 698 (6.8%) were 75 years and older. No overall differences in safety or effectiveness were observed between these subjects and younger subjects. Advanced age (≥65 years) is a risk factor for rosuvastatin calcium-associated myopathy and rhabdomyolysis. Dose selection for an elderly patient should be cautious, recognizing the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy and the higher risk of myopathy. Monitor geriatric patients receiving rosuvastatin calcium for the increased risk of myopathy [ see Warnings and Precautions (5.1) ]. 8.6 Renal Impairment Rosuvastatin exposure is not influenced by mild to moderate renal impairment (CLcr ≥30 mL/min/1.73 m 2 ). Exposure to rosuvastatin is increased to a clinically significant extent in patients with severe renal impairment (CLcr <30 mL/min/1.73 m 2 ) who are not receiving hemodialysis [ see Clinical Pharmacology (12.3) ]. Renal impairment is a risk factor for myopathy and rhabdomyolysis. Monitor all patients with renal impairment for development of myopathy. In patients with severe renal impairment not on hemodialysis, the recommended starting dosage is 5 mg daily and should not exceed 10 mg daily [s ee Dosage and Administration (2.5) and Warnings and Precautions (5.1) ]. 8.7 Hepatic Impairment Rosuvastatin calcium is contraindicated in patients with acute liver failure or decompensated cirrhosis. Chronic alcohol liver disease is known to increase rosuvastatin exposure. Patients who consume substantial quantities of alcohol and/or have a history of liver disease may be at increased risk for hepatic injury [ see Contraindications (4) , Warning and Precautions (5.3) and Clinical Pharmacology (12.3) ]. 8.8 Asian Patients Pharmacokinetic studies have demonstrated an approximate 2-fold increase in median exposure to rosuvastatin in Asian subjects when compared with White controls. Adjust the rosuvastatin calcium dosage in Asian patients [ see Dosage and Administration (2.4) and Clinical Pharmacology (12.3) ].
How supplied
Information about the available dosage forms to which the labeling applies, and for which the manufacturer or distributor is responsible. This field ordinarily includes the strength of the dosage form (in metric units), the units in which the dosage form is available for prescribing, appropriate information to facilitate identification of the dosage forms (such as shape, color, coating, scoring, and National Drug Code), and special handling and storage condition information.16 HOW SUPPLIED/STORAGE AND HANDLING Rosuvastatin tablets, USP are supplied as: Strength How Supplied NDC Tablet Description 5 mg Bottle of 90 tablets 72205-027-90 White, round shaped, biconvex, film coated tablets debossed with "R5" on one side and plain on other side. Bottle of 500 tablets 72205-027-05 Bottle of 1000 tablets 72205-027-99 Cartons of 100 (10 x 10) unit-dose tablets 72205-027-06 10 mg Bottle of 90 tablets 72205-003-90 Pink, round shaped, biconvex, film coated tablets debossed with "R10" on one side and plain on other side. Bottle of 500 tablets 72205-003-05 Bottle of 1000 tablets 72205-003-99 Cartons of 100 (10 x 10) unit-dose tablets 72205-003-06 20 mg Bottle of 90 tablets 72205-004-90 Pink, round shaped, biconvex, film coated tablets debossed with "R20" on one side and plain on other side. Bottle of 500 tablets 72205-004-05 Bottle of 1000 tablets 72205-004-99 Cartons of 100 (10 x 10) unit-dose tablets 72205-004-06 40 mg Bottle of 30 tablets 72205-005-30 Pink, oval shaped, biconvex, film coated tablets debossed with "R" on one side and "40" on other side. Bottle of 90 tablets 72205-005-90 Bottle of 500 tablets 72205-005-05 Bottle of 1000 tablets 72205-005-99 Cartons of 100 (10 x 10) unit-dose tablets 72205-005-06 Storage Store at controlled room temperature, 20ºC to 25ºC (68ºF to 77ºF); excursions permitted between 15°C and 30°C (59°F and 86°F) [see USP Controlled Room Temperature]. Protect from moisture.
| | | | |
| 5 mg | Bottle of 90 tablets | 72205-027-90 | White, round shaped, biconvex, film coated tablets debossed with "R5" on one side and plain on other side. |
| Bottle of 500 tablets | 72205-027-05 | ||
| Bottle of 1000 tablets | 72205-027-99 | ||
| Cartons of 100 (10 x 10) unit-dose tablets | 72205-027-06 | ||
| 10 mg | Bottle of 90 tablets | 72205-003-90 | Pink, round shaped, biconvex, film coated tablets debossed with "R10" on one side and plain on other side. |
| Bottle of 500 tablets | 72205-003-05 | ||
| Bottle of 1000 tablets | 72205-003-99 | ||
| Cartons of 100 (10 x 10) unit-dose tablets | 72205-003-06 | ||
| 20 mg | Bottle of 90 tablets | 72205-004-90 | Pink, round shaped, biconvex, film coated tablets debossed with "R20" on one side and plain on other side. |
| Bottle of 500 tablets | 72205-004-05 | ||
| Bottle of 1000 tablets | 72205-004-99 | ||
| Cartons of 100 (10 x 10) unit-dose tablets | 72205-004-06 | ||
| 40 mg | Bottle of 30 tablets | 72205-005-30 | Pink, oval shaped, biconvex, film coated tablets debossed with "R" on one side and "40" on other side. |
| Bottle of 90 tablets | 72205-005-90 | ||
| Bottle of 500 tablets | 72205-005-05 | ||
| Bottle of 1000 tablets | 72205-005-99 | ||
| Cartons of 100 (10 x 10) unit-dose tablets | 72205-005-06 |
Disclaimer: Do not rely on openFDA or Phanrmacy Near Me to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. Source: OpenFDA, Healthporta Drugs API